<SEC-DOCUMENT>0000856982-25-000035.txt : 20250520
<SEC-HEADER>0000856982-25-000035.hdr.sgml : 20250520
<ACCEPTANCE-DATETIME>20250520161645
ACCESSION NUMBER:		0000856982-25-000035
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		15
CONFORMED PERIOD OF REPORT:	20250516
ITEM INFORMATION:		Entry into a Material Definitive Agreement
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20250520
DATE AS OF CHANGE:		20250520

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			MERIT MEDICAL SYSTEMS INC
		CENTRAL INDEX KEY:			0000856982
		STANDARD INDUSTRIAL CLASSIFICATION:	SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
		ORGANIZATION NAME:           	08 Industrial Applications and Services
		EIN:				870447695
		STATE OF INCORPORATION:			UT
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-18592
		FILM NUMBER:		25969008

	BUSINESS ADDRESS:	
		STREET 1:		1600 WEST MERIT PARK WAY
		CITY:			SOUTH JORDAN
		STATE:			UT
		ZIP:			84095
		BUSINESS PHONE:		8012531600

	MAIL ADDRESS:	
		STREET 1:		1600 WEST MERIT PARKWAY
		CITY:			SOUTH JORDAN
		STATE:			UT
		ZIP:			84095
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>mmsi-20250516x8k.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<!-- iXBRL document created with: Toppan Merrill Bridge iXBRL 10.10.0.1 -->
<!-- Based on: iXBRL 1.1 -->
<!-- Created on: 5/20/2025 5:00:36 PM -->
<!-- iXBRL Library version: 1.0.9179.3415 -->
<!-- iXBRL Service Job ID: 8b3c2ea1-a3fb-4fc1-b019-69aa2e64a4da -->
<html xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns="http://www.w3.org/1999/xhtml" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mmsi="http://www.meritmedical.com/20250516" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2022-02-16" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:xbrli="http://www.xbrl.org/2003/instance"><head><meta http-equiv="content-type" content="text/html"/><title></title></head><body><div style="margin-top:30pt;"></div><div style="display:none;"><ix:header><ix:hidden><ix:nonNumeric contextRef="Duration_5_16_2025_To_5_16_2025_vgCLfz_rmkqZlxHvigqlTQ" name="dei:EntityCentralIndexKey" id="Tc_cVzWQdKh7kOiNbVtHlxGPg_2_1">0000856982</ix:nonNumeric><ix:nonNumeric contextRef="Duration_5_16_2025_To_5_16_2025_vgCLfz_rmkqZlxHvigqlTQ" name="dei:AmendmentFlag" id="Tc_KhXYW36uuEW1aAv2WAzdyQ_3_1">false</ix:nonNumeric></ix:hidden><ix:references><link:schemaRef xlink:href="mmsi-20250516.xsd" xlink:type="simple"/></ix:references><ix:resources><xbrli:context id="Duration_5_16_2025_To_5_16_2025_vgCLfz_rmkqZlxHvigqlTQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000856982</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2025-05-16</xbrli:startDate><xbrli:endDate>2025-05-16</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:27.35pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.43;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);min-height:50.24pt;"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1pt;padding-bottom:1pt;padding-top:1pt;border-bottom:1.0pt solid #000000;border-top:3.0pt solid #000000;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p><a id="_6a7d01a3_db3f_4a1a_bcba_6952adefcd3c"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:17pt;font-weight:bold;">UNITED STATES</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:17pt;font-weight:bold;">SECURITIES AND EXCHANGE COMMISSION</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Washington, D.C. 20549</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:17pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">FORM&#160;</b><ix:nonNumeric contextRef="Duration_5_16_2025_To_5_16_2025_vgCLfz_rmkqZlxHvigqlTQ" name="dei:DocumentType" id="Narr_xDzag7Udt0ujWC-nlgPdKw"><b style="font-weight:bold;">8-K</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:11pt;font-weight:bold;">CURRENT REPORT</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:11pt;font-weight:bold;">Pursuant to Section&#160;13 or 15(d)&#160;of the Securities Exchange Act of 1934</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;">Date of Report (date of earliest event reported): </span><ix:nonNumeric contextRef="Duration_5_16_2025_To_5_16_2025_vgCLfz_rmkqZlxHvigqlTQ" format="ixt:date-monthname-day-year-en" name="dei:DocumentPeriodEndDate" id="Narr_tUvifcr_jEK_s2eIyZZI2g"><span style="font-size:9pt;">May 16, 2025</span></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><img src="mmsi-20250516x8k001.jpg" alt="Graphic" style="display:inline-block;height:50.24pt;width:279.71pt;"/></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:17pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_5_16_2025_To_5_16_2025_vgCLfz_rmkqZlxHvigqlTQ" name="dei:EntityRegistrantName" id="Narr_58dpc45oIUyGiSTYjamg7Q"><b style="font-weight:bold;">Merit Medical Systems,&#160;Inc.</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">(Exact name of registrant as specified in its charter)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p><a id="_482e885a_2d52_4623_b7e4_21eef4425b9e"></a><a id="Tc_Iv3CZJHoP0mbQ-__hqKvwg_2_0"></a><a id="Tc_tvP9B0PcbEKF1D2gpdZznQ_2_2"></a><a id="Tc_mWSEftplpE2OBSZgWFthcg_2_4"></a><a id="Tc_XN8JmXv2-0WlkwEX6X07CA_3_0"></a><a id="Tc_c7tKaKjFW0ehciIAq-mIGQ_3_2"></a><a id="Tc_jvQEMwrl00mpB7tm-DJFRw_3_4"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0.5pt;padding-right:0.5pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:38.04%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:2.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:23.6%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:2.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:33.19%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:38.04%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_5_16_2025_To_5_16_2025_vgCLfz_rmkqZlxHvigqlTQ" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode" id="Tc_2WEFPxN60EuHJrjG6jbXHg_1_0"><b style="font-size:9pt;font-weight:bold;">Utah</b></ix:nonNumeric></p></td><td style="vertical-align:bottom;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;width:23.6%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_5_16_2025_To_5_16_2025_vgCLfz_rmkqZlxHvigqlTQ" name="dei:EntityFileNumber" id="Tc_gbmZwn46Hkq5xuXdNfMZgA_1_2"><b style="font-size:9pt;font-weight:bold;">0-18592</b></ix:nonNumeric></p></td><td style="vertical-align:bottom;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;width:33.19%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_5_16_2025_To_5_16_2025_vgCLfz_rmkqZlxHvigqlTQ" name="dei:EntityTaxIdentificationNumber" id="Tc_anGvr-2npUKO5VRv7kSyrQ_1_4"><b style="font-size:9pt;font-weight:bold;">87-0447695</b></ix:nonNumeric></p></td></tr><tr><td style="vertical-align:bottom;width:38.04%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">(State or other jurisdiction of</p></td><td style="vertical-align:bottom;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:23.6%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">(Commission</p></td><td style="vertical-align:bottom;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:33.19%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">(I.R.S. Employer</p></td></tr><tr><td style="vertical-align:bottom;width:38.04%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">incorporation or organization)</p></td><td style="vertical-align:bottom;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:23.6%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">File Number)</p></td><td style="vertical-align:bottom;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:33.19%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">Identification No.)</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p><a id="_7d471683_06d1_45fe_9287_288340eace6c"></a><a id="Tc_7uxAE-_iK06sqdy2Na92Pg_2_0"></a><a id="Tc_NLdGmt7cZkqSbtNCJYBxrw_3_0"></a><a id="Tc_bo614zRc90uM0EQSi5e5bQ_3_2"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0.5pt;padding-right:0.5pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:50.97%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:46.96%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:50.97%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_5_16_2025_To_5_16_2025_vgCLfz_rmkqZlxHvigqlTQ" name="dei:EntityAddressAddressLine1" id="Tc_X0WT8NOqSEWklHwtT9eHxw_1_0"><b style="font-size:9pt;font-weight:bold;">1600 West Merit Parkway</b></ix:nonNumeric></p></td><td style="vertical-align:bottom;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;width:46.96%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:50.97%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_5_16_2025_To_5_16_2025_vgCLfz_rmkqZlxHvigqlTQ" name="dei:EntityAddressCityOrTown" id="Narr_C0UeGfh5e0W-rHKMfQrl8A"><b style="font-size:9pt;font-weight:bold;">South Jordan</b></ix:nonNumeric><b style="font-size:9pt;font-weight:bold;">, </b><ix:nonNumeric contextRef="Duration_5_16_2025_To_5_16_2025_vgCLfz_rmkqZlxHvigqlTQ" format="ixt-sec:stateprovnameen" name="dei:EntityAddressStateOrProvince" id="Narr_U0ztLyHDfEG3FuIcYp60OQ"><b style="font-size:9pt;font-weight:bold;">Utah</b></ix:nonNumeric></p></td><td style="vertical-align:bottom;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:46.96%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_5_16_2025_To_5_16_2025_vgCLfz_rmkqZlxHvigqlTQ" name="dei:EntityAddressPostalZipCode" id="Tc_EIDu67yFSkeAvU1jJXbe1w_2_2"><b style="font-size:9pt;font-weight:bold;">84095</b></ix:nonNumeric></p></td></tr><tr><td style="vertical-align:bottom;width:50.97%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">(Address of principal executive offices)</p></td><td style="vertical-align:bottom;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:46.96%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">(Zip Code)</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:9pt;font-weight:bold;">(</b><ix:nonNumeric contextRef="Duration_5_16_2025_To_5_16_2025_vgCLfz_rmkqZlxHvigqlTQ" name="dei:CityAreaCode" id="Narr_hEwSPIleuEm3CnQgHsSZOw"><b style="font-size:9pt;font-weight:bold;">801</b></ix:nonNumeric><b style="font-size:9pt;font-weight:bold;">) </b><ix:nonNumeric contextRef="Duration_5_16_2025_To_5_16_2025_vgCLfz_rmkqZlxHvigqlTQ" name="dei:LocalPhoneNumber" id="Narr_7CGCoarYP0qoPorSwfoYWA"><b style="font-size:9pt;font-weight:bold;">253-1600</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">(Registrant's telephone number, including area code)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">N/A</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">(Former name or former address, if changed since last report)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:justify;margin:0pt;">Check the appropriate box below if the Form&#160;8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt;margin:0pt;"><ix:nonNumeric contextRef="Duration_5_16_2025_To_5_16_2025_vgCLfz_rmkqZlxHvigqlTQ" format="ixt-sec:boolballotbox" name="dei:WrittenCommunications" id="Narr_-DGH9K7K5kavZd8xC-_AQA"><span style="font-family:'Segoe UI Symbol';font-size:9pt;">&#9744;</span></ix:nonNumeric><span style="font-size:9pt;">&#160;&#160;&#160;Written communications pursuant to Rule&#160;425 under the Securities Act (17 CFR 230.425)</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:36pt;text-align:justify;text-indent:-36pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt;margin:0pt;"><ix:nonNumeric contextRef="Duration_5_16_2025_To_5_16_2025_vgCLfz_rmkqZlxHvigqlTQ" format="ixt-sec:boolballotbox" name="dei:SolicitingMaterial" id="Narr_t0QZxMttZUOwlnc2G5G7tA"><span style="font-family:'Segoe UI Symbol';font-size:9pt;">&#9744;</span></ix:nonNumeric><span style="font-size:9pt;">&#160;&#160;&#160;&#160;Soliciting material pursuant to Rule&#160;14a-12 under the Exchange Act (17 CFR 240.14a-12)</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:36pt;text-align:justify;text-indent:-36pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt;margin:0pt;"><ix:nonNumeric contextRef="Duration_5_16_2025_To_5_16_2025_vgCLfz_rmkqZlxHvigqlTQ" format="ixt-sec:boolballotbox" name="dei:PreCommencementTenderOffer" id="Narr_zPhKa0aXm0Cj_QJWq6P27g"><span style="font-family:'Segoe UI Symbol';font-size:9pt;">&#9744;</span></ix:nonNumeric><span style="font-size:9pt;">&#160;&#160;&#160;&#160;Pre-commencement communications pursuant to Rule&#160;14d-2(b)&#160;under the Exchange Act (17 CFR 240.14d-2(b))</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:36pt;text-align:justify;text-indent:-36pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt;margin:0pt;"><ix:nonNumeric contextRef="Duration_5_16_2025_To_5_16_2025_vgCLfz_rmkqZlxHvigqlTQ" format="ixt-sec:boolballotbox" name="dei:PreCommencementIssuerTenderOffer" id="Narr_In9Ejc358kKFgiwdwCEg2A"><span style="font-family:'Segoe UI Symbol';font-size:9pt;">&#9744;</span></ix:nonNumeric><span style="font-size:9pt;">&#160;&#160;&#160;&#160;Pre-commencement communications pursuant to Rule&#160;13e-4(c)&#160;under the Exchange Act (17 CFR 240.13e-4(c))</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:justify;margin:0pt;">Securities registered pursuant to Section 12(b) of the Act:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p><a id="_e1adca4e_7a42_4339_9783_775404ac1f0f"></a><a id="Tc_iOn7-1aI9kOO5W8cLkcpqg_1_0"></a><a id="Tc_ZVtcR4MyT0uvkPsWFvIoKA_1_2"></a><a id="Tc_X9tqyEQO9EKMqII-0Bfllg_1_4"></a><a id="Tc_l1aCyBLcaUmv9MVT6hsLsg_2_4"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:auto;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:31.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:2.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:20.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:3.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:42.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:31.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">Title&#160;of&#160;each&#160;class</p></td><td style="vertical-align:bottom;width:2.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;width:20.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">Trading&#160;Symbol(s)</p></td><td style="vertical-align:bottom;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;width:42.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">Name&#160;of&#160;each&#160;exchange&#160;on&#160;which&#160;registered</p></td></tr><tr><td style="vertical-align:top;width:31.7%;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_5_16_2025_To_5_16_2025_vgCLfz_rmkqZlxHvigqlTQ" name="dei:Security12bTitle" id="Tc_CmtpGVuv90CyTEtOljToug_2_0"><span style="font-size:9pt;">Common Stock, no par value</span></ix:nonNumeric></p></td><td style="vertical-align:top;width:2.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:20.06%;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_5_16_2025_To_5_16_2025_vgCLfz_rmkqZlxHvigqlTQ" name="dei:TradingSymbol" id="Tc_R9AmYcDbE0i0QRm1gLDE0Q_2_2"><span style="font-size:9pt;">MMSI</span></ix:nonNumeric></p></td><td style="vertical-align:top;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:42.39%;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_5_16_2025_To_5_16_2025_vgCLfz_rmkqZlxHvigqlTQ" name="dei:SecurityExchangeName" id="Narr_8HRJ3VKim0yYh7xZsLUlaw"><span style="font-size:9pt;">NASDAQ</span></ix:nonNumeric><span style="font-size:9pt;"> Global Select Market</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:justify;margin:0pt;">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:9pt;">Emerging growth company&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span><ix:nonNumeric contextRef="Duration_5_16_2025_To_5_16_2025_vgCLfz_rmkqZlxHvigqlTQ" format="ixt-sec:boolballotbox" name="dei:EntityEmergingGrowthCompany" id="Narr_1iydx7MW70O9afTUAVnWqw"><span style="font-family:'Segoe UI Symbol';font-size:9pt;">&#9744;</span></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:justify;margin:0pt;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. <span style="font-family:'Segoe UI Symbol';">&#9744;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-family:'Segoe UI Symbol';font-size:9pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-family:'Segoe UI Symbol';font-size:9pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:1pt;padding-top:1pt;border-bottom:3.0pt solid #000000;border-top:1px solid #000000;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="display:none;line-height:0pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:0pt;visibility:hidden;">&#8203;</span></p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.43;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_a7242462_aaaa_4182_971f_493daf3b12ea"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">Item&#160;1.01 Entry into a Material Definitive Agreement.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">On May 16, 2025, Merit Medical Systems, Inc., a Utah corporation (&#8220;Merit&#8221;), entered into an Agreement and Plan of Merger (the &#8220;Agreement&#8221;) by and among, Merit, Biolife, L.L.C., a Florida limited liability company (&#8220;FL Biolife&#8221;), Biolife Transaction Sub, LLC, a Delaware limited liability company (&#8220;Merger Sub&#8221;), and Shareholder Representative Services LLC, a Colorado limited liability company. Promptly following the execution of the Agreement, FL Biolife converted from a Florida limited liability company to a Delaware limited liability company called Biolife Delaware, L.L.C. (&#8220;Biolife&#8221;). Pursuant to the terms of the Agreement, on May 20, 2025, Merger Sub merged with and into Biolife, with Biolife continuing as the surviving corporation and a wholly-owned subsidiary of Merit (the &#8220;Merger&#8221;).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">Merit acquired Biolife through the Merger for a purchase price of $120 million (subject to standard adjustments for working capital and other matters). &#160;Merit paid the purchase price with available cash on hand.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">The Purchase Agreement contains customary representations and warranties, as well as customary indemnification provisions and post-closing covenants. &#160;The representations and warranties are insured pursuant to buyer-side representation and warranty insurance policy (the &#8220;RWI&#8221;), subject to standard exceptions and limitations, obtained by Merit in connection with the Acquisition. &#160;Recovery under the RWI is Merit&#8217;s sole recourse for breaches of representations and warranties, other than with respect to fraud. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">The foregoing summary of the principal terms of the Agreement is not complete and is qualified in its entirety by the actual terms and conditions of the Agreement, a copy of which Merit intends to file in a future filing with the U.S. Securities &amp; Exchange Commission. The representations, warranties, and other terms contained in the Agreement were made solely for the purposes of such agreement and as of specified dates, were solely for the benefit of the parties to the Agreement, and may be subject to limitations agreed upon by the contracting parties. Those representations and warranties may have been made for the purposes of allocating contractual risk between the parties to the Agreement instead of establishing these matters as facts, and may be subject to standards of materiality applicable to the contracting parties that differ from those applicable to investors. Investors are not third-party beneficiaries under the Agreement and should not rely on the representations, warranties and covenants or any descriptions thereof as characterizations of the actual state of facts or condition of Merit, Biolife, or any of their respective subsidiaries or affiliates. Accordingly, investors should not rely on the representations and warranties as characterizations of the actual state of facts, since (i) they were made only as of the date of the Agreement or prior, specified dates, (ii) in some cases they are subject to qualifications with respect to materiality, knowledge and/or other matters, and (iii) they may be modified in important part by the underlying exhibits and schedules.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Item 2.02. Results of Operations and Financial Condition.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">On May 20, 2025, Merit issued a press release announcing the Acquisition (the &#8220;Acquisition Press Release&#8221;) and updating its 2025 fiscal year guidance in light of the Acquisition. A copy of the Acquisition Press Release is furnished as Exhibit 99.1 to this Current Report on Form 8-K (this &#8220;Current Report&#8221;) and incorporated herein by reference.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Item 7.01 Regulation FD Disclosure</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"></span>On May 20, 2025, Merit issued the Acquisition Press Release announcing the Acquisition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"></span><span style="font-size:10pt;">The information contained in this Item 7.01 of this Current Report and in the attached Exhibit 99.1 is furnished pursuant to General Instruction B.2. of Form 8-K and shall not be deemed to be &#8220;filed&#8221; for purposes of Section 18 of the Exchange Act, or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing made by Merit under the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;), or the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;).</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">Merit is making reference to non-GAAP information in the Acquisition Press Release. A quantitative reconciliation of such non-GAAP financial information to comparable GAAP financial information is not available without unreasonable effort.</p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">2</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.43;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">The information included in this Current Report contains forward-looking statements about Merit that involve substantial risks and uncertainties. Merit intends such statements, and all subsequent forward-looking statements attributable to Merit, to be expressly qualified in their entirety by these cautionary statements and covered by the safe harbor provisions for forward-looking statements contained in Section 21E of the Exchange Act and Section 27A of the Securities Act. In some cases, forward-looking statements can be identified by the use of terminology such as &#8220;anticipate,&#8221; &#8220;believe,&#8221; &#8220;continue,&#8221; &#8220;estimate,&#8221; &#8220;expect,&#8221; &#8220;forecast,&#8221; &#8220;intend,&#8221; &#8220;may,&#8221; &#8220;might,&#8221; &#8220;plan,&#8221; &#8220;potential,&#8221; &#8220;project,&#8221; &#8220;will,&#8221; &#8220;would,&#8221; &#8220;seek,&#8221; &#8220;should,&#8221; &#8220;could,&#8221; &#8220;can,&#8221; &#8220;predict,&#8221; &#8220;potential,&#8221; &#8220;continue,&#8221; &#8220;objective&#8221; or other forms of these words or similar words or expressions, or the negative thereof or other comparable terminology. However, not all forward-looking statements contain such identifying words. All statements included in this Current Report, other than statements of historical fact, are forward-looking statements for purposes of the Exchange Act and the Securities Act, including any projections of earnings, revenues or other financial items, any statements of the plans and objectives for future operations, any statements concerning proposed new products or services, any statements regarding the integration, development or commercialization of the business or any assets acquired from other parties, any statements regarding future economic conditions or performance, and any statements of assumptions underlying any of the foregoing. Additionally, forward-looking statements include, among other things, inherent risks and uncertainties associated with Merit&#8217;s acquisition of Biolife, Merit&#8217;s integration of the Biolife business and operations and its ability to achieve projected financial results, product development and other anticipated benefits of the Acquisition, and uncertainties as to whether Merit will achieve sales, gross and operating margin, net income and earnings per share performance consistent with its forecasts projected for the Biolife Acquisition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause Merit&#8217;s actual results, levels of activity, performance or achievement to be materially different from those expressed or implied by these forward-looking statements, including those risks, uncertainties and other factors described in Merit&#8217;s Annual Report on Form 10-K for the year ended December 31, 2024 and Merit&#8217;s Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2025, and subsequent filings with the SEC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">All forward-looking statements included in this Current Report speak only as of the date made, are based on information available to Merit as of such date, and are subject to change. Merit assumes no obligation to update or revise any forward-looking statement. If Merit does update or correct one or more forward-looking statements, readers should not conclude that Merit will make additional updates or corrections. Merit&#8217;s actual results will likely differ, and may differ materially, from anticipated results. Readers should not unduly rely on any such forward-looking statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_0c74a69b_cfac_4e80_8149_d8a437ccccfb"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">3</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.43;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Item 9.01. Financial Statements and Exhibits.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">(d)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; Exhibits</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:15.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:1.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style="height:34.5pt;"><td style="vertical-align:bottom;width:15.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">EXHIBIT&#160;NUMBER</b></p></td><td style="vertical-align:top;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;width:83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">DESCRIPTION</b></p></td></tr><tr style="height:14.5pt;"><td style="vertical-align:top;width:15.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:6pt 0pt 0pt 0pt;">99.1</p></td><td style="vertical-align:top;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:6pt 0pt 0pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:6pt 0pt 0pt 0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="mmsi-20250516xex99d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Press release issued by Merit Medical Systems, Inc., dated May 20, 2025, entitled &#8220;Merit Medical Acquires Biolife Delaware, L.L.C.&#8221;</span></a></p></td></tr><tr style="height:15.4pt;"><td style="vertical-align:top;width:15.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:6pt 0pt 0pt 0pt;">104</p></td><td style="vertical-align:top;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:6pt 0pt 0pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:6pt 0pt 0pt 0pt;">The cover page from this Current Report on Form 8-K, formatted in Inline XBRL</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><a id="_e41c4e77_278c_4866_b318_093099dab7df"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">SIGNATURES</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0.5pt;padding-right:0.5pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:50.19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:4.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:45.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:50.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:49.8%;margin:0pt;padding:0pt 2pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">MERIT MEDICAL SYSTEMS,&#160;INC.</b></p></td></tr><tr><td style="vertical-align:bottom;width:50.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:4.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:45.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:50.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:4.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:45.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:50.19%;margin:0pt;padding:0pt 2pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Date: May 20, 2025</p></td><td style="vertical-align:bottom;width:4.1%;margin:0pt;padding:0pt 2pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:</p></td><td style="vertical-align:bottom;width:45.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 2pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="text-decoration-color:#000000;">/s/ Brian G. Lloyd</span></p></td></tr><tr><td style="vertical-align:bottom;width:50.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:4.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:45.7%;border-top:1px solid #000000;margin:0pt;padding:0pt 2pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Brian G. Lloyd</p></td></tr><tr><td style="vertical-align:bottom;width:50.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:4.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:45.7%;margin:0pt;padding:0pt 2pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Chief Legal Officer and Corporate Secretary</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">4</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;margin-left:10.35%;margin-right:10.35%;margin-top:30pt;page-break-after:avoid;width:79.3%;border:0;"></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>mmsi-20250516xex99d1.htm
<DESCRIPTION>EX-99.1
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  10.10.0.134--><!--Created on: 5/20/2025 05:00:35 PM (UTC)--><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 0pt 7.5pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">EXHIBIT 99.1</b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt;"><a name="_Hlk54257290"></a><a name="_Hlk529444201"></a><font style="font-family:'Times New Roman','Times','serif';"><img src="mmsi-20250516xex99d1001.jpg" alt="Graphic" style="display:inline-block;height:75.75pt;left:0%;padding-bottom:0.75pt;position:relative;top:0pt;width:468pt;"></font></p><div style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt;"><div style="display:inline-block;width:465.75pt;"><div style="left:0pt;padding-bottom:0pt;position:relative;top:0pt;width:465.75pt;"><div style="left:0pt;position:relative;text-indent:0pt;top:0pt;"><div align="left"><table style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:16pt;height:max-content;line-height:1.28;margin-bottom:0pt;margin-top:0pt;padding-left:0pt;padding-right:0pt;width:312.2pt;"><tr style="height:1pt;"><td style="font-family:'Calibri','Helvetica','sans-serif';line-height:1.28;vertical-align:top;width:1.05pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;width:100%;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="font-family:'Calibri','Helvetica','sans-serif';line-height:1.28;vertical-align:top;width:174.6pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;width:100%;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="font-family:'Calibri','Helvetica','sans-serif';line-height:1.28;vertical-align:top;width:136.55pt;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;width:100%;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="font-family:'Calibri','Helvetica','sans-serif';line-height:1.28;vertical-align:top;width:1.05pt;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;width:100%;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="font-family:'Calibri','Helvetica','sans-serif';line-height:1.28;vertical-align:top;width:174.6pt;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;width:100%;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="font-family:'Calibri','Helvetica','sans-serif';line-height:1.28;vertical-align:top;width:136.55pt;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;width:100%;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="font-family:'Calibri','Helvetica','sans-serif';line-height:1.28;vertical-align:top;width:1.05pt;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;width:100%;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="font-family:'Calibri','Helvetica','sans-serif';line-height:1.28;vertical-align:top;width:174.6pt;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;width:100%;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Contacts:</b><font style="font-family:'Times New Roman','Times','serif';">&#160;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;width:100%;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">&#160;</font></p></td><td style="font-family:'Calibri','Helvetica','sans-serif';line-height:1.28;vertical-align:top;width:136.55pt;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;width:100%;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="font-family:'Calibri','Helvetica','sans-serif';line-height:1.28;vertical-align:top;width:1.05pt;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;width:100%;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="font-family:'Calibri','Helvetica','sans-serif';line-height:1.28;vertical-align:top;width:174.6pt;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;width:100%;background:#ffffff;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">PR/Media Inquiries:</b><font style="font-family:'Times New Roman','Times','serif';">&#160;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;width:100%;background:#ffffff;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">Sarah Comstock&#160;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;width:100%;background:#ffffff;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">Merit Medical&#160;</font></p></td><td style="font-family:'Calibri','Helvetica','sans-serif';line-height:1.28;vertical-align:top;width:136.55pt;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;width:100%;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Investor Inquiries:</b><font style="font-family:'Times New Roman','Times','serif';">&#160;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;width:100%;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">Mike Piccinino, CFA, IRC&#160;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;width:100%;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">ICR Healthcare&#160;</font></p></td></tr><tr><td style="font-family:'Calibri','Helvetica','sans-serif';line-height:1.28;vertical-align:top;width:1.05pt;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;width:100%;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="font-family:'Calibri','Helvetica','sans-serif';line-height:1.28;vertical-align:top;width:174.6pt;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;width:100%;background:#ffffff;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">+1-801-432-2864&#160;</font></p></td><td style="font-family:'Calibri','Helvetica','sans-serif';line-height:1.28;vertical-align:top;width:136.55pt;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;width:100%;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">+1-443-213-0509&#160;</font></p></td></tr><tr><td style="font-family:'Calibri','Helvetica','sans-serif';line-height:1.28;vertical-align:top;width:1.05pt;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;width:100%;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="font-family:'Calibri','Helvetica','sans-serif';line-height:1.28;vertical-align:top;width:174.6pt;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;width:100%;background:#ffffff;margin:0pt;"><u style="color:#0000ff;font-family:'Times New Roman','Times','serif';text-decoration-color:#0000ff;text-decoration-line:underline;text-decoration-style:solid;">sarah.comstock@merit.com</u><font style="color:#0000ff;font-family:'Times New Roman','Times','serif';">&#160;</font></p></td><td style="font-family:'Calibri','Helvetica','sans-serif';line-height:1.28;vertical-align:top;width:136.55pt;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:1.19;width:100%;margin:0pt;"><u style="color:#0000ff;font-family:'Times New Roman','Times','serif';text-decoration-color:#0000ff;text-decoration-line:underline;text-decoration-style:solid;">mike.piccinino@icrhealthcare.com</u><font style="color:#0000ff;font-family:'Times New Roman','Times','serif';">&#160;</font></p></td></tr></table></div><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;width:100%;margin:0pt;"><font style="margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></div></div></div></div><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:16pt;font-weight:bold;">Merit Medical Acquires Biolife Delaware, L.L.C.</b></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.27;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:italic;font-weight:normal;">Acquired business offers the StatSeal&#174; and WoundSeal&#174; products, which provide hemostasis solutions that complement the wide range of procedures Merit&#8217;s portfolio supports.</i></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.27;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:italic;font-weight:normal;">Acquisition projected to add approximately $18 million of revenue, on an annualized basis beginning in fiscal year 2026, with a mid-teens growth and accretive non-GAAP margin and profitability profile</i></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.27;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:italic;font-weight:normal;">Merit reaffirms full-year 2025 financial guidance previously issued on April 24, 2025, and updates full-year 2025 financial guidance to include the projected impact from this acquisition </i></td></tr></table><div style="margin-top:8pt;"></div><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;text-align:justify;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">SOUTH JORDAN, Utah, May 20, 2025 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ: MMSI), a global leader of healthcare technology, today announced that it has acquired Biolife Delaware, L.L.C. (&#8220;Biolife&#8221;) in a merger transaction through which Biolife has become a wholly-owned subsidiary of Merit. Biolife, which is headquartered in Sarasota, Florida, manufactures unique patented hemostatic devices under the brand names StatSeal and WoundSeal.</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;text-align:justify;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">The aggregate transaction consideration, paid in cash and assumption of Biolife liabilities, was approximately $120 million. This strategic acquisition positions Merit to provide clinicians with more products designed to standardize, simplify, and minimize post-procedure care and maintenance.</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;text-align:justify;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">Many Merit products operate through small openings in the skin that require efficient solutions to stop bleeding, help patients recover, and minimize costly complications. In such cases, StatSeal&#160;specifically works with the patient&#8217;s blood to rapidly form a protective seal over the procedure site. Adding StatSeal to Merit&#8217;s hemostasis portfolio is intended to provide healthcare partners with an additional effective solution that complements a wide range of percutaneous procedures, including interventional radiology and cardiology, dialysis, electrophysiology, biopsy, and drainage.</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;text-align:justify;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">&quot;We are excited to enhance the portfolio of hemostatic solutions offered to clinicians with the acquisition of Biolife,&#8221; said Fred P. Lampropoulos, Merit&#8217;s Chairman and Chief Executive Officer. &#8220;The acquisition provides effective, differentiated, hemostatic solutions for all percutaneous devices with a broad range of clinical applications including vascular closure and indwelling catheter bleeding complications. BioLife&#8217;s StatSeal and WoundSeal products address an estimated $350M global market opportunity, are clinically validated, and will enhance our ability to deliver comprehensive solutions to our customers. Moreover, with </font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;text-align:justify;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">Merit&#8217;s resources and expertise, we believe we are well positioned to further develop and expand the reach of these product lines, ultimately benefiting patients and healthcare providers globally.&#8221;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;text-align:justify;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">Mr. Lampropoulos continued, &#8220;We have updated our full-year 2025 financial guidance to include the projected impact of this acquisition from the merger effective date of May 20, 2025 to December 31, 2025 and we have reaffirmed our updated full-year 2025 financial guidance previously issued on April 24, 2025. While we anticipate the transaction will be slightly dilutive to our full-year 2025 non-GAAP profitability given the partial-year contribution, we believe the financial profile of this acquisition is very attractive and is consistent with our goal of delivering sustainable, constant currency growth, improving profitability and strong free cash flow generation. We look forward to discussing this acquisition in further detail on our second quarter earnings report on July 30, 2025.&#8221;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;text-align:justify;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">Non-GAAP net income; non-GAAP earnings per share; non-GAAP gross margin; non-GAAP operating margin and constant currency revenue are non-GAAP financial measures. A quantitative reconciliation of such financial measures to comparable GAAP financial measures is not available without unreasonable effort.</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;text-align:justify;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">For more information about Merit Medical and the StatSeal and WoundSeal product lines, please visit </font><font style="font-family:'Times New Roman','Times','serif';">www.merit.com</font><font style="font-family:'Times New Roman','Times','serif';">.</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Financial Summary</b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;text-align:justify;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">Merit believes that the acquired assets generated approximately $15 million of revenue over the twelve-month period ended December 31, 2024. The acquired assets are expected to contribute revenue, from the merger effective date of May 20, 2025 through December 31, 2025, in the range of $10 to $11 million and are projected, during the same period of time, to dilute Merit&#8217;s previously forecasted non-GAAP net income and non-GAAP earnings per share, inclusive of approximately $3.0 million of lower interest income on cash balances used for the total purchase consideration and excluding approximately $7.2 million of non-cash and non-recurring transaction-related expenses, and to be dilutive to Merit&#8217;s full-year 2025 GAAP net income and GAAP earnings per share.</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;text-align:justify;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">The acquisition is projected to be accretive to non-GAAP gross margin, non-GAAP operating margin in 2025 and slightly accretive to non-GAAP net income and non-GAAP earnings per share in 2026. The acquisition is projected to be dilutive to Merit&#8217;s GAAP net income and GAAP earnings per share in the first full-year post close and accretive thereafter.</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Updated Fiscal Year 2025 Financial Guidance</b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;text-align:justify;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">Merit&#8217;s updated full-year 2025 financial guidance now reflects the projected impacts of the Biolife acquisition from the merger effective date of May 20, 2025 through December 31, 2025. Merit is otherwise reaffirming prior full-year 2025 financial guidance previously announced on April 24, 2025.</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;text-align:justify;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">Based upon the information currently available to Merit&#8217;s management, for the year ending December 31, 2025, after giving effect to the Biolife acquisition and absent material acquisitions, non-recurring transactions or other factors beyond Merit&#8217;s current expectations, Merit now expects the following financial results:</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 6pt 0pt;"><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">Revenue and Earnings Guidance*</i></p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;" align="center"><tr style="height:1pt;"><td style="vertical-align:bottom;width:34.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:1pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:1pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:20.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:1pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:1pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:20.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:1pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:1pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:34.38%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:center;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:31.72%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Updated Guidance</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:31.69%;border-bottom:1px solid #000000;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Prior Guidance</b><sup style="font-family:'Times New Roman','Times','serif';font-size:7.5pt;font-weight:bold;vertical-align:top;">(2)</sup></p></td></tr><tr><td style="vertical-align:bottom;width:34.38%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Financial Measure</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.27%;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Year Ending</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.44%;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">% Change </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.27%;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Year Ending</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.42%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">% Change </b></p></td></tr><tr><td style="vertical-align:bottom;width:34.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:center;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.27%;border-bottom:1px solid #000000;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">December 31, 2025</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.44%;border-bottom:1px solid #000000;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Y/Y</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.27%;border-bottom:1px solid #000000;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">December 31, 2025</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Y/Y</b></p></td></tr><tr><td style="vertical-align:bottom;width:34.38%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.27%;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:center;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.44%;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:center;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.27%;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:center;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.42%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:center;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:34.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;line-height:1.19;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Net Sales</b></p></td><td style="vertical-align:bottom;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:9pt;font-weight:bold;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:20.27%;background:#cceeff;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">$1.480&#160;- $1.501 billion</b></p></td><td style="vertical-align:bottom;width:11.44%;background:#cceeff;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">9% - 11%</b></p></td><td style="vertical-align:bottom;width:20.27%;background:#cceeff;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">$1.470&#160;- $1.490 billion</b></p></td><td style="vertical-align:bottom;width:11.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">8% - 10%</b></p></td></tr><tr><td style="vertical-align:bottom;width:34.38%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;line-height:1.19;margin:0pt 0pt 0pt 6pt;"><font style="font-family:'Times New Roman','Times','serif';">Cardiovascular Segment</font></p></td><td style="vertical-align:bottom;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt 0pt 0pt 6pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.28;margin-bottom:8pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:20.27%;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;line-height:1.19;text-align:center;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">$1.407&#160;- $1.426 billion</font></p></td><td style="vertical-align:bottom;width:11.44%;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;line-height:1.19;text-align:center;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">8% - 10%</font></p></td><td style="vertical-align:bottom;width:20.27%;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;line-height:1.19;text-align:center;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">$1.397&#160;- $1.415 billion</font></p></td><td style="vertical-align:bottom;width:11.42%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;line-height:1.19;text-align:center;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">7% - 9%</font></p></td></tr><tr><td style="vertical-align:bottom;width:34.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;line-height:1.19;margin:0pt 0pt 0pt 6pt;"><font style="font-family:'Times New Roman','Times','serif';">Endoscopy Segment</font></p></td><td style="vertical-align:bottom;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt 0pt 0pt 6pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.28;margin-bottom:8pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:20.27%;background:#cceeff;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;line-height:1.19;text-align:center;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">$73.0&#160;- $75.0 million</font></p></td><td style="vertical-align:bottom;width:11.44%;background:#cceeff;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;line-height:1.19;text-align:center;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">34% - 37%</font></p></td><td style="vertical-align:bottom;width:20.27%;background:#cceeff;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;line-height:1.19;text-align:center;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">$73.0&#160;- $75.0 million</font></p></td><td style="vertical-align:bottom;width:11.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;line-height:1.19;text-align:center;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">34% - 37%</font></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:34.38%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt 0pt 0pt 6pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.28;margin-bottom:8pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt 0pt 0pt 6pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.28;margin-bottom:8pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.27%;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:center;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.44%;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:center;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.27%;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:center;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.42%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:center;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:34.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;line-height:1.19;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Non-GAAP</b></p></td><td style="vertical-align:bottom;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:9pt;font-weight:bold;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:20.27%;background:#cceeff;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">&#160;&#160;</b></p></td><td style="vertical-align:bottom;width:11.44%;background:#cceeff;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:center;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:9pt;font-weight:bold;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:20.27%;background:#cceeff;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">&#160;&#160;</b></p></td><td style="vertical-align:bottom;width:11.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:center;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:9pt;font-weight:bold;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:34.38%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;margin:0pt 0pt 0pt 6pt;"><font style="font-family:'Times New Roman','Times','serif';">Earnings Per Share</font><sup style="font-family:'Times New Roman','Times','serif';font-size:6.75pt;vertical-align:top;">(1)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt 0pt 0pt 6pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.28;margin-bottom:8pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.27%;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;line-height:1.19;text-align:center;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">$3.28 - $3.41</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.44%;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;line-height:1.19;text-align:center;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">(5%) - (1%)</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.27%;border-left:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;line-height:1.19;text-align:center;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">$3.29 - $3.42</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.42%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;line-height:1.19;text-align:center;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">(5%) - (1%)</font></p></td></tr></table></div><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;line-height:1.28;margin-bottom:8pt;visibility:hidden;background:#ffff00;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;line-height:1.19;text-align:justify;margin:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-style:italic;background:#ffffff;">*Percentage figures approximated; dollar figures may not foot due to rounding</i></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;line-height:1.19;text-align:justify;margin:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-style:italic;background:#ffffff;">(1) Merit&#8217;s non-GAAP earnings per share reflect the dilutive impact of its 3.00% Convertible Senior Notes due 2029 (the &#8220;Convertible Notes&#8221;) calculated using the if-converted method of approximately $0.05 for the year ending December 31, 2025. Any offsetting impacts of the capped call associated with the Convertible Notes are not considered</i></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;line-height:1.19;text-align:justify;margin:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-style:italic;background:#ffffff;">(2) &#8220;Prior Guidance&#8221; reflects Merit&#8217;s full-year 2025 financial guidance, previously updated on April 24, 2025.</i></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt 0pt 6pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 6pt 0pt;"><i style="font-family:'Times New Roman','Times','serif';font-style:italic;">2025 Net Sales Guidance - % Change from Prior Year (Constant Currency) Reconciliation*</i></p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;" align="center"><tr style="height:1pt;"><td style="vertical-align:bottom;width:60.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:1pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:1pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:1pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:1pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:1pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:1pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:1pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:1pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:1pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:60.35%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:18.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Updated Guidance</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:18.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Prior Guidance</b><sup style="font-family:'Times New Roman','Times','serif';font-size:7.5pt;font-weight:bold;vertical-align:top;">(1)</sup></p></td></tr><tr><td style="vertical-align:bottom;width:60.35%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Low</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">High</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Low</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">High</b></p></td></tr><tr><td style="vertical-align:bottom;width:60.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">2025 Net Sales Guidance - % Change from Prior Year (GAAP) </font></p></td><td style="vertical-align:bottom;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:8.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;line-height:1.19;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">9.1%</font></p></td><td style="vertical-align:bottom;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:8.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;line-height:1.19;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">10.7%</font></p></td><td style="vertical-align:bottom;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:8.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;line-height:1.19;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">8.4%</font></p></td><td style="vertical-align:bottom;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:8.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;line-height:1.19;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">9.8%</font></p></td></tr><tr><td style="vertical-align:bottom;width:60.35%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">Estimated impact of foreign currency exchange rate fluctuations</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;line-height:1.19;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">0.4%</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;line-height:1.19;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">0.4%</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;line-height:1.19;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">0.4%</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;line-height:1.19;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">0.4%</font></p></td></tr><tr><td style="vertical-align:bottom;width:60.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;line-height:1.19;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">2025 Net Sales Guidance - % Change from Prior Year (Constant Currency) </font></p></td><td style="vertical-align:bottom;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:8.21%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;line-height:1.19;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">9.5%</font></p></td><td style="vertical-align:bottom;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:8.21%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;line-height:1.19;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">11.0%</font></p></td><td style="vertical-align:bottom;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:8.21%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;line-height:1.19;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">8.7%</font></p></td><td style="vertical-align:bottom;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:8.2%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;line-height:1.19;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">10.2%</font></p></td></tr></table></div><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;line-height:1.28;margin-bottom:8pt;visibility:hidden;background:#ffff00;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;line-height:1.19;text-align:justify;margin:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-style:italic;background:#ffffff;">*Percentage figures approximated and may not foot due to rounding</i></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;line-height:1.19;text-align:justify;margin:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-style:italic;background:#ffffff;">(1)&#8220;Prior Guidance&#8221; reflects Merit&#8217;s full-year 2025 financial guidance, previously introduced on April 24, 2025.</i></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:justify;margin:10pt 0pt 10pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">Merit does not provide guidance for GAAP reported financial measures (other than revenue) or a reconciliation of forward-looking non-GAAP financial measures to the most directly comparable GAAP reported financial measures (other than revenue) because Merit is unable to predict with reasonable certainty the financial impact of various items which could impact Merit&#8217;s future financial results, such as expenses attributable to acquisitions or other extraordinary transactions, non-cash expenses related to amortization or write-off of previously acquired tangible and intangible assets, certain employee termination benefits, performance-based stock compensation expenses, expenses resulting from non-ordinary course litigation or administrative proceedings and resulting settlements, governmental proceedings, and changes in governmental or industry regulations. These items are uncertain, depend on various factors, and could have a material impact on GAAP reported results for the guidance period. For the same reasons, Merit is unable to address the significance of the unavailable information, which could be material to future results. Specifically, Merit is not, without unreasonable effort, able to reliably predict the impact of these items and Merit believes inclusion of a reconciliation of these forward-looking non-GAAP measures to their GAAP counterparts could be confusing to investors or cause undue reliance.</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">Merit&#8217;s financial guidance for the&#160;year ending December&#160;31, 2025 is subject to risks and uncertainties identified in this release and Merit&#8217;s filings with the U.S. Securities and Exchange Commission (the &#8220;SEC&#8221;). This guidance is based on information and estimates available to Merit as of May 20, 2025. Should known or unknown risks or uncertainties materialize or should underlying assumptions prove inaccurate, actual results will likely vary, and could vary materially, from past results and those anticipated, estimated or projected.</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Advisors:</b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;text-align:justify;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">Piper Sandler &amp; Co. acted as a financial advisor to Merit. Parr Brown Gee &amp; Loveless P.C. served as legal advisor to Merit. Nelson Mullins Riley &amp; Scarborough LLP served as legal advisor to Biolife.</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">ABOUT MERIT</b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;text-align:justify;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">Founded in 1987, Merit Medical Systems, Inc. is engaged in the development, manufacture, and distribution of proprietary medical devices used in interventional, diagnostic, and therapeutic procedures, particularly in cardiology, radiology, oncology, critical care, and endoscopy. Merit serves customers worldwide with a domestic and international sales force and clinical support team totaling more than 800 individuals. Merit employs approximately 7,300 people worldwide.</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">ABOUT BIOLIFE, L.L.C.</b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;text-align:justify;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">Biolife Delaware, L.L.C., headquartered in Sarasota, Florida, manufactures innovative healthcare and first-aid solutions designed to improve patient quality of life.&#160;Biolife&#8217;s products consist of a powder with two main ingredients: potassium ferrate and a hydrophilic polymer.&#160;The products work independently of the clotting cascade to seal the wound or vascular access site while accelerating hemostasis.&#160;StatSeal products for the healthcare industry are available in powder and disc (compressed powder) form. WoundSeal products for the consumer and occupational health industries are available in powder form.</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS</b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;text-align:justify;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements include, among others:</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">statements proceeded or followed by, or that include the words, &#8220;may,&#8221; &#8220;will,&#8221; &#8220;should,&#8221; &#8220;expects,&#8221; &#8220;plans,&#8221; &#8220;anticipates,&#8221; &#8220;intends,&#8221; &#8220;seeks,&#8221; &#8220;believes,&#8221; &#8220;estimates,&#8221; &#8220;projects,&#8221; &#8220;forecasts,&#8221; &#8220;potential,&#8221; &#8220;target,&#8221; &#8220;continue,&#8221; &#8220;upcoming,&#8221; &#8220;optimistic&#8221; or other forms of these words or similar words or expressions, or the negative thereof or other comparable terminology;</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">statements that address Merit&#8217;s future operating performance or events or developments that Merit&#8217;s management expects or anticipates will occur, including, without limitation, any statements regarding Merit&#8217;s projected revenues, earnings or other financial measures, Merit&#8217;s plans and objectives for future operations, Merit&#8217;s proposed new products or services, the integration, development or commercialization of the business or any assets acquired from other parties, future economic conditions or performance, the implementation of, and results which may be achieved through, Merit&#8217;s Continued Growth Initiatives Program or other business optimization initiatives, and any statements of assumptions underlying any of the foregoing; and</font></td></tr></table></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">statements regarding Merit&#8217;s past performance, efforts, or results about which inferences or assumptions may be made, including statements proceeded or followed by the words &quot;preliminary,&quot; &quot;initial,&quot; &quot;potential,&quot; &quot;possible,&quot; &quot;diligence,&quot; &quot;industry-leading,&quot; &quot;compliant,&quot; &quot;indications,&quot; or &quot;early feedback&quot; or other forms of these words or similar words or expressions, or the negative thereof or other comparable terminology.</font></td></tr></table><div style="margin-top:8pt;"></div><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;text-align:justify;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">The forward-looking statements contained in this release are based on Merit management&#8217;s current expectations and assumptions regarding future events or outcomes. If underlying expectations or assumptions prove inaccurate, or risks or uncertainties materialize, actual results will likely differ, and could differ materially, from Merit&#8217;s expectations reflected in any forward-looking statements. Financial estimates are subject to change and are not intended to be relied upon as predictions of future operating results. Investors are cautioned not to unduly rely on any such forward-looking statements.</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;text-align:justify;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">The following are some of the important risks and uncertainties that could cause Merit&#8217;s actual results to differ from Merit&#8217;s expectations in any forward-looking statements: inherent risks and uncertainties associated with Merit&#8217;s acquisition of Biolife; Merit&#8217;s integration of the Biolife business and operations and its ability to achieve projected financial results, product development and other anticipated benefits of the acquisition; uncertainties as to whether Merit will achieve sales, gross and operating margin, net income and earnings per share performance consistent with its forecasts projected for the Biolife acquisition; risks and uncertainties regarding trade policies or related actions implemented by the U.S. or other countries, including existing, proposed or prospective tariffs, duties or other measures; inherent risks and uncertainties associated with Merit&#8217;s integration of businesses or assets previously acquired from third parties, including the acquisitions of certain businesses and assets from Cook Medical Holdings LLC in November 2024 and EndoGastric Solutions, Inc. in July 2024, and Merit&#8217;s ability to achieve the anticipated operating and financial results, product development and other anticipated benefits of such acquisitions; forecasted results and consequences of regulatory approvals of Merit&#8217;s products; effects of Merit&#8217;s 3.00% Convertible Senior Notes due 2029 on Merit&#8217;s net income and earnings per share performance; disruptions in Merit&#8217;s supply chain, manufacturing or sterilization processes; U.S. and global political, economic, competitive, reimbursement and regulatory conditions; reduced availability of, and price increases associated with, components and other raw materials; increases in transportation expenses; risks relating to Merit&#8217;s potential inability to successfully manage growth through acquisitions generally, including the inability to effectively integrate acquired operations or products or commercialize technology developed internally or acquired through completed, proposed or future transactions; fluctuations in interest or foreign currency exchange rates and inflation; risks and uncertainties associated with Merit&#8217;s information technology systems, including the potential for breaches of security and evolving regulations regarding privacy and data protection; governmental scrutiny and regulation of the medical device industry, including governmental inquiries, investigations and proceedings involving Merit; difficulties relating to development, testing and regulatory approval, clearance and maintenance of Merit&#8217;s products; the safety, efficacy and patient and physician adoption of Merit&#8217;s products; uncertainties regarding enrollment and outcomes of ongoing and future clinical trials and market studies relating to Merit&#8217;s products; modification or limitation of governmental or private insurance reimbursement policies; litigation and other judicial proceedings affecting Merit; the potential of fines, penalties or other adverse consequences if Merit&#8217;s employees or agents violate the U.S. Foreign Corrupt Practices Act or other laws or regulations; consequences associated with a Corporate Integrity Agreement executed between Merit and the U.S. Department of Justice; restrictions on Merit&#8217;s liquidity or business operations resulting from its debt agreements; infringement of Merit&#8217;s technology or the assertion that Merit&#8217;s technology infringes the rights of other parties; product recalls and product liability claims; potential for significant adverse changes in governing regulations; changes in tax laws and regulations in the United States or other jurisdictions or exposure to additional tax </font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;text-align:justify;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">liabilities which may adversely affect Merit&#8217;s effective tax rate; termination of relationships with Merit&#8217;s suppliers, or failure of such suppliers to perform; development of new products and technology that could render Merit&#8217;s existing or future products obsolete; market acceptance of new products; dependence on distributors to commercialize Merit&#8217;s products in various jurisdictions outside the U.S.; failure to comply with applicable environmental laws; changes in key personnel; labor shortages and increases in labor costs; price and product competition; extreme weather events; and geopolitical events. For a further discussion of the risks and uncertainties which may affect Merit&#8217;s business, operations and financial condition, see Part I, Item 1A, &#8220;Risk Factors&#8221; in Merit&#8217;s Annual Report on Form 10-K for the year ended December 31, 2024 filed with the U.S. Securities and Exchange Commission (the &#8220;SEC&#8221;), Part II, Item 1A, &#8220;Risk Factors&#8221; in Merit&#8217;s Quarterly Report on Form 10-Q for the quarter ended March 31, 2025 filed with the SEC and Merit&#8217;s other filings with the SEC.</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;text-align:justify;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">All subsequent forward-looking statements attributable to Merit or persons acting on its behalf are expressly qualified in their entirety by these cautionary statements. Actual results will likely differ, and may differ materially, from anticipated results. Financial estimates are subject to change and are not intended to be relied upon as predictions of future operating results. Those estimates and all other forward-looking statements included in this release are made only as of the date of this release, and except as otherwise required by applicable law, Merit assumes no obligation to update or disclose revisions to estimates and all other forward-looking statements.</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><u style="font-family:'Times New Roman','Times','serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">TRADEMARKS</u></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;text-align:justify;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">Unless noted otherwise, trademarks and registered trademarks used in this release are the property of Merit Medical Systems, Inc.,&#8239;its subsidiaries, or its licensors.</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:avoid;width:76.47%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>mmsi-20250516x8k001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 mmsi-20250516x8k001.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" !# 74# 2(  A$! Q$!_\0
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M/V@/AI874MM<>/?#T4\3%70ZC%E2.HZU#_PT7\+O^B@>'?\ P8Q_XU/MJ?\
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M1D]C7VOKWPK\)ZSX#N?"<V@V*:"ULT*6D<"JL0VX#)@?*PZAASGFN _9'^"
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M^6,>6^_^>GW7WU\CT(U:*PKKUZOMO9M.-T]&T[0?,M;OWG'6*4&D_>.T\%?
M7P-X&T\P6F@6E_>2_-=:IJD2W5Y=N?O/+*X+,2>?3T K@OC-\/M-^$&G7'Q3
M\"V$/A[5]$*7.JV6G((;;5K$,!/%-$N%+A"75\;@R]>:9\=/C+JVC?%CX?\
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MK],_V!_^3<M,_P"PA>_^CC7YF3$-/*0<@NQ!'?DU^F?[ _\ R;EIG_80O?\
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M'5$@V[?+%SC=TXS][WSS5WPQ^U]\4_"'@N+PQI^OQ_88(O(M[FXMEENK>/&
MJ2'T' + D<8/%>K_ /#MGQ?_ -#GH?\ X"S?XT?\.V?%_P#T.>A_^ LW^-"H
M8U:I/[_^"*6;<)3CRRE3:O?X'O\ ^ _UJ>.Q_M3?$6/1H[(ZI:2WT5N;2/7I
M;&-]5CA((*+=$;AP2-WWO?/-6]4_:^^*FL>!W\+7/B)6L9(/LTMVMNJWDL6,
M%6EZ\C@L &/KS7J__#MGQ?\ ]#GH?_@+-_C1_P .V?%__0YZ'_X"S?XT>PQO
M9_?_ ,$'FO"3:DY4[IW7N/?_ ,!/D(    8 [5^F_P"P/_R;EIG_ &$+W_T<
M:\'B_P"";'BPRH)/&FBK&2-S):3$@>PR,_G7VC\(OAAIOP=^'VE>%-+EDN8+
M)6+W,P >>5F+/(0.!EB>.PP.U=N PU6E5<YQLK'RW&O$&6YCE\<-A*O/+F3T
M3T23[I=R+XO_  A\/_&SP=+X=\0QR^1Y@G@N;=@LUM*,@.A((S@D$$$$$@UY
MS\"OV.?"GP0\1OXABO[WQ!K:HT5M<7JHBVRL,,411]XC(W$G@D#&37OE%>S*
MA3E-5''5'Y11S;'4,+/!4JK5*6\>GG]_6V_4\Z^./P-T#X\^$TT;6VFM9;>7
MS[._M<>;;28P2,@@@@X*GK[$ CB?@#^Q_P"&O@3KDVO+J5UXAUUHV@AN[J-8
MDMXV^]L1<X8]"Q)XX&,G/O=%#H4I351Q]X=/-\?1PDL!3JM4I;Q_/SL^J3LS
MS3X[_ 3P_P#'WPU;Z9K,D]E=6<AFLM1M<>;;L1AA@\,K#&5/H.A KYW_ .':
M&E_]% O_ /P6Q_\ Q=?:=%14PM&K+FG&[.S \19KEM'V&%K.,.UD_NNG8^+/
M^':&E_\ 10;_ /\ !;'_ /%T?\.T-+_Z*#?_ /@MC_\ BZ^TZ*R^H8;^7\7_
M )GH_P"N6>_]!/\ Y+#_ .1/E/X<_P#!/CPKX,\66.M:MXAOO$J6,JSPV,MN
MD$+2*<J9,$E@" =O ..<CBOJRBBNFE1IT5:FK'@9AFF-S6:J8VHYM:+96^2L
MCYC^,'[!_A?XG>,;WQ)I^N7GAF\OW\Z[@@@2:"24_>D"D@J6ZGG!.3CDUPO_
M  [0L/\ HH5W_P""I/\ XY7VM17/+!8>3<G'\SV*'%F=8:E&C3Q#Y8JRNHO3
MU:;/FKX*_L-^&OA)XRM?$UWK=WXEU&R):R2>!(88'((\PJ"2S $XR<#KC."/
M?O%WA33/'7AC4_#^LVPN]+U&!K>XA)QN4^A[$<$'L0#6O16].C3I1<(+1GCX
MS-<;F%>.)Q-5RFK6>UK:JUK):ZZ=3Y7\"?\ !/KP?X/\;6NN7FNZCKUG93BX
MMM,NHHT3>IRGFLO+@$ XPH)'.1Q7K7CSX4ZS>^,D\9^"/$47AKQ.UJMC>I>6
MGVJRU&!6+1B6,,K!T+-M=2#@D'(KTZBHCAJ4(\L5;^NYTU\]S'%5E7Q%7G:5
MM4FK=4U:SOZ;I/=(\U^'?PHU+1/%5[XQ\7Z^OBCQ?<VPL8YX;86UK86V[<8;
M>++$;FP69B6; Z 5FZ[\)?%>A>+]8\1?#GQ19:&VN.L^J:1K%@;NSEN H3[1
M'M=&C<J%##)#8!(S7KE%7[&'+R_KK]YRK,\3[5U6T[JS7*N6RV7+:UE:ZLM'
MKN<#\+?A;)X$GUG6=8UB3Q+XNUR1)-2U>6$0AE08CABC&1'$@)PN222222:Y
MN\^#?BSPIX@UC4/AQXQM?#^GZQ<M?7FB:OIOVVU2Y;_62P%71H]YY9<E2<D8
MS7L5%/V,+*/;[_O!9EB55E5;3<K)IQBXV6RY6K*UM++3I8\=_P"$6^.7_0_^
M$?\ PFY?_DFC_A%OCE_T/_A'_P )N7_Y)KV*BI]C'N_O9I_:E7_GW3_\%P_^
M1/'?^$6^.7_0_P#A'_PFY?\ Y)JE-^S/_P )-:ZKJ7B_Q5>:QXXO/L[6GB&T
M@6V_L@P/YD(M(LD(H<DMN)+Y.37M]%#P\'\5WZMLI9OBH:TN6#[QA&+T=[72
MO;NMGU/&O^%>_&#6H_L.K_%'3].L -C76@:"L5[.OJ7ED=(V/JJ_2NV^'7PI
M\._"^SNH]&MI7O;U_-OM4OIFN+V]D_O33-\S'T'0=@*Z^BJC1A%\V[\W?\SG
MK9AB*T'2;48O=1C&*?KRI7\KWMT/)?$7PC\3:5XQU;Q-\//%-KX>N=:*/JNE
MZK8&[LKB95""X4*Z-')M"@X.&VC(R,UN_"WX72> Y=9U;5]9E\2^+-<E274M
M6EB$*L$4K'#%&"1'$@)PN2<DDDDUWM%"HPC+F7]?(*F8XBI1]C)JUDF[*[2M
M9.5KM*RT;Z+LK>=^/O@;H'CG68]?AGO_  QXLB3RX_$&@S_9[HJ.B2<%94_V
M9%8>F*PAX(^,^F@0V7Q.T34X ,";5O#?[\#W,4R*Q_X"*]AHI.C!NZT?DVOR
M*IYEB(05-M22VYHQE;R7,FTO):'C4G[/^I>-98V^)?CB_P#&5BA#_P!A6ENN
MG:8Y'(\V*,EY1[.Y'J*]@M+6&PM8;:VACMK:%!''#"H5$4# 50.  .,"I:*N
M%.,-C#$8ROBDHU'HMDDDEZ)))7ZZ:F#X\\$:5\1_">H^'=;B>73[U KF)RDD
M; ADD1A]UU8*P/8@5YQ;^ ?C-I4,=I:?%#1KZUA 2.XU3PYONG4=/,9)E5F]
M6"C/6O9:*4J49OF>_DVBZ&.K8>'LHV<;WM*,9)/NN9.U]+VWLK[(\?\ ^$0^
M-I/_ "4?PP![>&'_ /DFF0_!CQ7XMUK2KGXB^-H/$6E:7=)?6^B:7I8L;::X
M0YCDG)=VD"'Y@F0,@$YQ7L=%1["'5M_-G1_:N(7P*$7W4()KT:C=>JU"BBBN
M@\<**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
+"BBB@ HHHH __]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>mmsi-20250516xex99d1001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 mmsi-20250516xex99d1001.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" !F G8# 2(  A$! Q$!_\0
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MOBN"0QL5888<$'M7C5\1-3:B[6/U'*,FPDL)"K7AS.2OK^1]UI_P52^([_\
M,J^&/^^;C_XY4R?\%2_B.W_,K>&?^^;C_P".5\06\H/>K\,F:XWB:R^T?2PR
M3+'_ ,N5^/\ F?:H_P""HWQ&/_,K>&?^^;C_ ..4X?\ !43XBG_F5_#7_?-Q
M_P#'*^,T((J50*S^M5OYCKCD&5O_ )<+\?\ ,^RA_P %0?B*?^97\-?]\S__
M !RG#_@I_P#$4G_D6/#7_?,__P <KXX J08I?6JW\QLN'LK?_+A?C_F?8H_X
M*>_$3_H6/#7_ 'S/_P#'*>/^"G/Q#_Z%GPW_ -\S_P#QROCQ1@>]. S4_6ZW
M\QJN'<J_Y\+\?\S[#_X><?$,C_D6/#?_ 'S/_P#'*4?\%-OB'_T+/AO_ +YG
M_P#CE?'X%. I?6Z_\QJN&\I_Z!U^/^9]@#_@IK\0_P#H6/#?_?,__P <I1_P
M4T^(1_YEGPW_ -\S_P#QROD #-/"T?6Z_P#,:KAK*?\ H'7X_P"9]>C_ (*8
M_$(_\RSX<_[YG_\ CE.'_!3#XA?]"SX<_P"^9_\ XY7R&%XIP6I^N5_YC1<,
MY0_^8=?C_F?7G_#R_P"(/_0L^'/^^9__ (Y2_P##R[X@_P#0M>'/^^9__CE?
M(F,TX"I^N5_YS5<,9/\ ] \?Q_S/KG_AY=\0?^A9\.?]\S__ !RE_P"'EGQ!
M_P"A:\.?]\S_ /QROD8"G8H^N5_YS1<+Y/\ ] \?Q_S/KC_AY7\0/^A:\._]
M\S__ !RC_AY5\0/^A:\._P#?,_\ \<KY)VTNRE]=K_SLK_5;)O\ H&C^/^9]
M;#_@I3\0?^A:\._]\S__ !RE_P"'E'Q!_P"A;\._]\S_ /QRODH+2[32^NXC
M^<M<*Y-_T#1_'_,^M/\ AY1\0?\ H6_#G_?,_P#\<I?^'D_Q!_Z%KP[_ -\S
M_P#QRODL"@K[4OKN(_G92X4R;_H&C^/^9]:?\/)_B!_T+7AW_OF?_P".4?\
M#R?X@?\ 0M^'?^^9_P#XY7R9MHV^U+Z[B/YV/_53)O\ H&C^/^9]9_\ #R?X
M@_\ 0M^'?^^9_P#XY6==_P#!37XE6C?-X6\-,AZ,%N,?^C*^7=E(\0=2K $'
MJ#5+'5UO(RJ<(Y1)>[ATG\_\SZ<'_!4'XB'_ )E?PU_WS<?_ !RGC_@I]\1#
M_P RQX:_[YG_ /CE?)-[H[1DO!DKW3N/I6>#6ZQE9[2/'GPSEM*7+/#K\?\
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MQ _Z%OP[_P!\S_\ QROD-E:-L."I]",4!JT^N8C^<Y_]6<FV>&C^/^9]>_\
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MN]-W#S5T^:6&8+W*ERRY]B.?45\7:KH^HZ(T2ZCI]WI[3)YD2W<#Q%U_O+N
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M<^RO%<WL:Z?*FWNM%N]4MO(\? S3L5]G#_@F5XF _P"1WTG_ , Y?_BJ4?\
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ML@0DG@,<*3_%CFG:#\#]6UGPQKNJS74.G7&DR3126%PI$A>(9D4\_*1]#ZG
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MGD#->9_$KXO>$?'^H7NL_P#"':A%X@D:,P3WFL^?:P*C#;$+<1*/*"@J$!
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MZ:R6M]U?N>AVGA;4_@9X6^*NO6>K+?Z\MOI4>E>([-F#M97[-(UU&Q^9'D1
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MY1DP. 1*C9&>#5QA33LW_5[')7Q>-E2<HQLUMHWK[-RO]^B5M_,^>=<TB_\
M#FIW&FZI:2V%_;D+-;3##QD@'!'T(-=+J?P5\?:/X3_X2:^\):I::%Y8F-[-
M#M"QGH[*3N"G(^8@#D<UGZ-IMAH-K;:[<ZIIUY<:;K$$+Z"A9Y;J%?G:56 V
M&,[=G7/S#BO6?BAI^@:_\0-=^)EM\1-,UJQOKT:E;Z%,ER-1F4R*_P!BEC*!
M$51E2Q8KA1C/2LXP5FW^9V5<154XP@K]WRMW>FBMM>^[;7KJ>5ZE\(O&VE^'
M6UV[\,:C;Z4L2W#W#Q\QQ-]V1TSO5#D89@!R.>:=X?\ @IX_\6VJW6C>$-6U
M&V>V^V)-#;G;)#EAN0G[WW6X&3P>*]P&M>'-'^-GBWXJR>-;'5M&U6+4)(-$
M3S#J%U]JA>-+.:(KM14,BY8MMQ&-N>!56R^(>CV_BC]FX-KRC3/"UM:_V@/-
M8)92?;7:4L/7R]N3SQ@5IRT[[G$Z^,E'W8=+[/31NUM[II*^F^UU8\'U?X5>
M,M#\(V_BG4/#.I6?AZX=8X]0F@*QEF^Z#W7.#@D 'MFN1D@G(SL*C_:XKZ"N
M?BCI<V@?'TZGK:3W_B":WEL%E<L]XR7Q?*?2,YYZ"OFN]U.?4I?*C&U3_"/Z
MFERK3E-X59>\JNZ:M;S2?7LW;Y;+8_5O_@E,<_L^^(OF#X\37 RO3_CVMJ*;
M_P $H[;[+^SSKZ9W$^)9R3[_ &:VHKZ&A_"B?B><W_M"M?N?.?\ P5*./VC-
M+_[%ZW_]'SU\@*^,5]A_\%1K,W'[1.EL'"G_ (1ZW&"/^FT]?'YL9EZ -]#7
MAXAKVLC];R:,O[/HNW1"E\H1WQ7[@_!#4/#GC3]G?P9:375AJFF7/A^UM+B%
MI%9&Q"J2(PSU!!!'4$5^'15X_OHR_45-#=20C"2NBGG"L0,TZ%;V+;M>YGFV
M5_VI"$>?D<7?:_ZH_;G7OV<OA'XJTV"RUK0;+5TAG%PDU]?2S3[@H4 S-(7*
MX &PL5QVJ_=_ [X7WZW<5QHFGSV=S$\3V#W#&T0.NUFC@W^7&Q'!=%#>_-?A
M^M_<?\_$O_?PU*M].?\ EXE_[^'_ !KH^N0_Y]K^OD>(N&<0TE]<E]S_ /DC
M]I="_9D^#GAG3XK#2_#EA96*@B6VBO91%=C.[%POF8G /02[@.U='\,/A1\.
M_@Q;:A;^#-*T[08[^4377DS%FE89QEF8G R<+G R<"OP]6_G_P">\O\ W\-1
MW(DNQDW$R2=F$A_7FA8V*?P?U]P3X5KU(M2Q;=]TT]?_ "8^C/\ @HEXAT_6
MOVGM7.GWD-[';6%K;3- X=4D"DLA(XR,C([5R&M_M<?$KQ1\*K?X>:AKB2>'
MHXDMF*P*MQ-"F-D3R=2HP!V) &2:\(EBELWQ(."?O#H:EBN>E<,ZDI2E).US
MZK#X2E2HTJ%6*E[.UFUU75=CZ ^'_P"US\2/AM\.+GP1H6KPP:-*)!$\EN'N
M+4/G>(GS\N22>0<$DC%0? _]IGQM\ CJ2>%[NV-KJ!5[BTOX/.C9U& XY!#8
M.,@\]^@KQ.*X]ZM1SYK/VDTT[[;'HK"X2<9QE234W>6BU?=GU\O_  4C^+3#
M_5>'O_ !_P#XY1-_P4;^+<\#HO\ 8,#L"!(E@Q*^XRY&?J*^2XYJLQS\=:;Q
M%;^=BADN5?\ 0/'[CL=(^(&OZ+XVB\7VFI2IXCCNS?"^."S3%B69AT.<G(Z$
M$BOH2/\ X*+?%@(H*: Y P6-@W/_ )$KY124<<U.DO2L(U:E._))H]BO@,#C
M7%XFC&5M%=;+L>D?%WXW>*OCAXAMM7\4744D]K%Y-M#:1>5%"N<G:,DY)Y))
M)X'H*ZCQI^UG\2?'_A/2_#^JZQ$+33Y8;A9K> 1SS21$-&TC]RI / &2 3FO
M%5D%2*]9.I4U?,]=ST(X'!.-./LHVI_#HO=].QZ+XD^+=UX@TG4[.VT+2-"E
MUAUDU:[TR)TDOB&WX;<Y6-"^'*1A06 ..!5N^^-6HWUG>2+H^E6WB*^M/L-Y
MXBACD%Y/"5",,%_+5V4;6=5#,,Y/)KS-7J57K-SGO<[(8/#))<FWKY;]UHM'
MIHNR.^T[XGQ'1=.T[7?"NC^)QIT7V>TN;YIXIXH<EA&6AD3>H).-V2,X!Q5@
M?$3PWC_DF7A[_P #-0_^2*\]#5(K9J?:2_I(ZEA*+;:NO24DON32/2+#XPKX
M;F-YX6\):+X7UD*4BU:T>YFN+<$8)C\Z5U5B"1N R 3BGR_&BXCO)=3TSPOX
M>T?Q!.QDEUBWM7DF\P\F2-)':.)B<G**,$Y&*\VZT\&I]K-=399?A6[RC=^;
M;NNSN]5Y.Z\CKO#OQ&NM)M]3M-4TZS\4Z=J-PMW<6NKF1MUPN0)A(CJX?#,"
M=WS X.:6;XI>(V\8R^)K6]73]1>-8 EI&JP+ JA%@\LY4Q!%5=C @@<YKD<T
MO6LW4EM<ZU@\.Y2FX*[5GVMITVULK][*^QZ WQ0TZ=_M%S\/O"L]_P!?/6*X
MA0GU,*3",_3;CVK"\4^.M9\8W$$FH7*I#;)Y5M9VD8@MK9,YVQQ)A5'<]SU)
M)KGZ4=*4IRDK7-J6#H4I*<8ZK:[;MZ7;M\K'6>'OB#-I&B2Z+J&DZ?XCTAI_
MM4=KJ?F9MYBH5GC>-U==P !&<':..*OCXBZ&!C_A6_AOCUEO?_DBN%I<T*I)
M+_ABW@J$Y.5FK]I27X)I&QXL\57OC+5S?WB00;(DMX+:TC\N&WA0;4C1>R@?
M4GDDDFL;%.!]Z#G ]*R<FW=G;3I0I14(*R6PW&:*=UH(I7->5#<48I<4$47%
MRB8JI=Z;%<Y;&Q_[R_UJY252DT[HQJ485(\LU='/3V<MH3N&5_O#I40:NF(!
M'/2J%SI$<N6C/E-Z=C71&JGN>'7RZ4?>I._D98-.#4D]K-:GYU.W^\.140DK
M;?8\E\T'RR5F3[Z=N!J#S!2AZ!\Z)LB@G%1;Z-^>]%A\R)=U&ZHLY%)NQ0+F
M)"W^332:87I"],GF0I--8YI"X]:87S32,7(<DTD+?NW9?H:LIK$\?W@L@]Q@
MU2)IC&AQ3W01KU*?P2:-F/7(6'SJR'\Q5B.\AF^Y*K'ZUS1J-N]3[)=#H68U
M5\5F=86J-FKF%NYH?N2LOX\5*NM7"#YMK_44O9,O^T8/XDT;[/41:LI=>4_?
MB(]U-/76;5^K%/J*.1KH'UNE+:1?9C49>H!?P2?=E0_C09 W0Y^E.Q#JI[,>
MSU&STQGJ-FJDCFE,<SU&S8IK/4;/5V.>4AS/^%1,]2)!+/RD;$>N.*G32)&P
M9'"^R\FBZ1*A4G\**#/D4Q5>0X12Q]A6U'IT$?5=Y]6.:FVA1@  >@I<ZZ&B
MPDG\3,9-+F?[V$'OS4R:3$O+LSG\A5^2>./[\BJ/<U2FU6W0'#ES_LBA.3$Z
M=&G\7XDR01Q#Y$5?H*1C6;-K9_Y9Q@>['^E9ESJ,TV=\AQZ#@52@WN<]3$TX
MZ1-BZU&"V!W."W]U>36#?:Y(^1'^[7U[U2GG"YYJDJR7LFQ. .K'H*WC!(\B
MMBIST0QC)>S;$RS'DD_UK4MK-+:/ Y8]6[FE@BCM$VH,GN>YIWF\X +-V JV
M^B.>$%'5[GZI?\$L1C]G_7_^QDG_ /2:VHH_X)8I(G[/^O>8NTGQ).0/;[-;
M45]%A_X43\0SO_D8UO4^>/\ @IW_ ,G#Z9_V+]O_ .CIZ^25KZV_X*=_\G#Z
M9_V+]O\ ^CIZ^25KP,1_&EZG[)D?_(NH?X42"D>UAD/S1K]1Q2BOH3]G_0M;
MOOA-XYU#PIX+T_QEXFM]6TN&.*\T2+4VAMW2Z,I5)%.T$I'EACH*PA'FE8];
M$5HX>DZDDGJEJ[+5I;_,^=CI:'E'9?8\U$VGS+]W#CV->S?'[1M-T;Q7HB0:
M;I^B:Y/I<,VO:1I3AK6ROB[AD0!F"$QB)F0$A68CCH/H'XK>!I=.\1>/H_%?
M@3PKX=^&EI!=IH^M6UC;6-Y]H6'-JL#1$/,[2;0RLI^4L3C&:T5-N^NW]?(X
MJF,I15.7+\:;W5]&EHOM-WTMNMCX4.Z,X=2OU%2))QUKZ#_9ET=M5'Q!EM].
MT#4-5L_#ZSV/_"2P6\MI%*;RW1G/GCRP=C. 3ZUQ/QA@O[KQ6D&M6?ANSO+>
M!%V^$X+6&U922P)^SC8S\\GJ.!4-6BI,ZXR<L1*A"WN^>NR>W;7>YYLS)*I1
ML,#U!K.NM+,?SP'*_P!PG^5?4_Q:AOM?\$:A<^!-.\)ZK\-HK:WVPV6G0KJN
MB$! 6G; F#EPP:4ED;=UY&.6^ E]:V.@>([+3Y?#VF_$"XGMSI=WXIMXI+:6
MW <301/*K1Q2LQC.7QN (##O?):7*G_7D<;Q#G0=64-4[6OMM\6FEKZJSMN?
M.Z3%&P<@CL:MQW'/6NS^*6E:FGCG6(?$>AP>'=:64?:-/L[=;>*)MHY1%RH5
MOO#;\IW9'!%,^#'A^*^^,_@.RO;>*_TVYU^PAN(9D#I)&UP@974\$$$@CI2M
M>7*5*4J=+VRU5KZ?U^)S,5SGO5N.X&.M?27Q:\+:EIW@?QU=?$?P/X6\&B*0
MKX1N]*L[:PO;R<72KY8B@/[V+R?,+,Z_*0O.3BN8_9ITRYO_  !\1K_2M-\*
MWVNV<FFK;3>+(+22VA1Y)1)M-R-@8@+[G%6Z+YN4YJ>:)T76MLTM]-;=?*^O
MS/'(Y^G-64GZ<YK5^)>I:E<^.KM-7MM!M;^#RX9(_#<-O%9'"@@H(/W9.#R1
MU/6NB_:+L++0?CQXYT[3;2"PL+;4WCAM;:,1QQ* /E51P!["L)0LF^Q[5+&<
MTH1?VDWY:6_S..2;WJ9)O>O?OA-I>J?\*$TW4O#NE>!I]3F\17UO=77BZVL7
M=HDM[9HTC:Z[!G<D+TW<]:\-O/[0\3^,)K>.UMFU2^O?)2UTR)(X3,S[0D2)
M\H4L< +QZ5,Z?*EYF^&QZK3G'1*-UOKIW73[R)90:D$@'4XKV/XS^"/#5MX.
MCD\)HLEWX)ND\/>(9XR"+N5P76[&/X3-Y\.?1(^>:B^!FJVR^$]9T_0YO#EG
M\09KZ)[63Q-!"\5U9["&MX'F!CCD,F"=V-P( /%)T;2Y6S>&:J6']O"/6UGI
M;S>]E:SVV9Y,LOO4JR XYKJHK*];XU65CXAT2#2+V36[>*]TE+8111%ID#1B
M+D!2#T'&#QQ7I/[1 U[19M=L;C2_ -GH?]K2V]K_ &!::>M]&B2MY88PCS%&
MU0&SCT-9>Q]UR['=_:2C6ITE;WU??\M-?P/$!)BI X-41+BI5E%<SB>_&L6]
MU.#"JRRU()*AHZHU43@TX-Q4 ;-/#5+1TQJ$VZES4(:G;JFQNJA+FC<:9NS2
MYJ;&RF/SFC--!S12L7S(=F@FFYHS18?,APZ4VC-&:+"Y@I":,T52,VQ#TP><
M]C5&YTF&;)3]TWJO3\JO$TTFJ3:V.:K3A55IJYS]QI\]MDD;U'\2\U6$E=.3
MFJMQ807&2R8;^\O!KHC4[GA5L!K>D_O,/S:7?D58N-'E3)B82#T/!K/D#PG:
MZE3Z'BMU9['DU(U*6DT3ASZTIDJJ)*/,IV,.<LE\BD+?C5?S*3S*+"YR?>*0
MR5!Y@QUIIDIV)YR8O32^*A,@SUIIDS3L9N9,7J-GJ(R>],,F.].QDYDC-FHV
M:F&6F-)^%58Q<QS' J-CQ2-)4>2[8 )/M3,F[G>_#O3]/U3P;\2!>:=:W5Q9
M:(E]:7<BMYUM*+RWCRA!Q@K*P((/;IBNHT;X3:>?A= (M2TJ?X@^(+635+/2
M[QI5E@T^+>V82%\OSI?+D8!V!V+A1ELCS70]2U?1K/6;2T9((-6M/L-V)4!+
M1>8DN!W4[HT.1Z8[UU>D_$KQ%I/AR+1TN;-TAMI;*WO7L(6O;>WDW>9#'<%=
MZH=[C / =@, UK&<%N>=5PF*FVZ3M=IZOR7X7U:6_<]*TSX=^'/%GCG6OAU%
MI4>D_P!@'3_+U^"60W=T7N;:"X,NYBA$GV@LF%&W:H&<G/!>,19>+/ %YXAT
MKP[;>%KC2]=72EAM'D*7%M)%(Z&3S&8F5#$06&-P?D<"HKWXK>)+S1H-.-U!
M!Y?V</>V]K''>7 @QY EG4;Y!'A=N3_"O7 JMXR^)>N>.H(8-3:SC@BF>Y,5
MA9QVR2SN 'FD" ;Y& &6/X8R:<JD&M%_7_ '0P&*A-.I4TT^T^VOKS=NG0]$
M\+?"?1_%^G:-KTW^@:9JFB+I<*0<*-?W- @)/9BBS,/1SVIEQ\!]2U7^QK'2
MX+:PN+6*WTV\GG@FE>XU.5//D1O+5O+6)98HV=MJKCOSCRVW\9ZQ9:#9Z-!?
M/%IUIJ/]K00CHESM5?,'OA5_*M3_ (6UXCD?5C=SV^I+JE])J5Q'?0"51<O]
MZ50>A(P".A &1P*GGIM:HT^K8RG)RIU/2]W;M^&YVWAGX)WLGB/PC:>(]6BL
M++76;FTMY9-N%<[!*$,1<%,,H8E3C(].9^$.BZ5XG^)"66O:@W_"+VMO=75]
M?01E2L,<3$2 'D?-LX/TJAI/QA\1^'K+3K337LK*&RO(K]1#9H/.GC5D1I1C
M#_*[ \<Y.<US.F^([W1X]6CM&CA75+9K.Y C!S$SJY5?[N2B].W'>I_=JS2.
MB^.E&:G5W5E9[:O7ULU;5['K<GP-U#3_  %XBCO'DE\;0ZM%#I]E$<"6S6X%
MK),.VUYIH@I]$)Z5F2_LV>(_M(CEUC3[>W3[8EQ>7@G@AA>VB,LHR\8+IM#;
M70$$J1Z9Y2?XQ^+)KX7LFK.]V-*@T99F4%DMH61H@I[,K1HP;KD9J#4/B[KU
M[?7-Z1807=U;W%M<306:(TRSJ5E+>Y!/3 !)(%:?NNQPM9AKS5%K_DM/0ZR]
M^$6A0^#M8U635EM9K'0[34;5XFEFCOC+=-#YI!C4QA@  AY4X)/4"[\(_#NE
M7'PPN-7O=*\)W;#Q"EG=W7BF\:W$=I]G#L(2LBL6SD_(&;VKS*?XH:V^D3:8
M\\$EE+I<6CM&T"G_ $>.7S8\'LROSNZ]JYVX\7WO_",?\(_YJ?V6+W^T/+V#
M=YWE^7G=UQMXQTJE*-[I&$Z59P<93W?X?@>F>(_@Y:/J6MOHVNVB6\=E)KEA
MIMRDIN6TTN/)=V"; [1LC[2<X(S@\5KZI^SY_9?@[QC:-JFD7^L>'=7A35-6
MM7E,&FVRPW!E1R5&XEDBX0,=Q5<YS7EJ_''Q%9:0U@AT^0G3O[(^W362-=?9
M,@B'S<9VC  [@ #..*DTCXN>-FU?4]2@OQ#/J6J?VO=A+=,33[9$8,I&/+99
M9%:,_*P;D5JE36K1P26,J>Y"6W_ \O7_ ()?T_\ 9]\6>(K*+4--%O?:5+!8
M7$=U&Y =;J0Q@ $9)C<,LG]PCTQ6F/@?+:V]Y$?$>E17EKIAUHV:I,[-9;E"
MR[@FT%E99 I.=I&<'BJ^D?$'Q=I5E;6EKK#:;86J7T=O9V:!(X4NQB=%'93V
M'\)Y&#6E:?$K6K/0I-+1+!U?3#HS7DMFC77V/C$/F]<#  [@ #.!BLG4I[(]
M"G@\=>[:6OSM]W]7\C!\6?"35_!)N!J\\$9CU&;3XTB8LUQY2J6F3C_5D.F#
MWW>QK&AM(K5<1J >Y/4UZ9XZ^)5MXKTO[$;&6[DMK.PTVPU&]"B2"W@1O,^4
M9 >20@ELG"J%YZUYTW2L)M7]W8]7"TY1IWJKWC].O^"8'_)!M=_[&.?_ -)[
M>BC_ ()@_P#)!==_[&.?_P!)[>BOIL-_!B?@^??\C.O_ (CYO_X*>_\ )P^F
M?]B_;_\ HZ>ODE:^N?\ @J! \7[06CR,I"2^'H"C=CB><&OD5:\+$_QI'Z_D
M;_X3J'^%$HKLM'\>#2OA?XA\)K;R>;JNI6-^+M)-HC%NDZE".IW>>.<\;?>N
M-%2#I7*FT]#WG"-16EW3^YW7XDL;;7!]#FO9M0^/T.O^-/'$^KZ-)?\ @WQ9
M<-=7&B/./,M9@N(KB"3&$E0]\8925/%>,+3UH4G'8JIAZ=:SFMO\T_ONEKT/
M0OA7XYT/P?'XKL-?TN^U;2=?TP:=(EC<I;S1XN(I@P9E8=8@,8[UC>+KKPO/
MJ5N_A;3-2TZP5!YL.J7:7#N^3DAD10!C QC-<VO45+4<S:L=$*$(U'55[O?5
MVVMMML>P6OQ(^'_A33]=N_"7AK7K/7]7TR?2VBU+4HY[&TCF7;*R;4#R'&=H
M?@9!YQ7)^";[P+'I]W:^,-(UNZE:0/;WVB7D<<B+C!C:.52K GG=D$<]:XX=
M:>M#FVRH82G%22;N^O,[Z;:W_KJ=5\5O%MG\2/%$=_;:<VF:?9V-MIEE;O-Y
MLJ6\$8CC\R3 WN0,DXQS@<"L?P'J'_"$>._#GB(1&\32=1M[\VV[89!%(K[0
MW.,[<9]ZSUZU(.E3[25^;J;K!T/9*CRZ6M\O4Z6Y^(\>K>%_$WAGQ)I,NHZ-
M?7<^IZ1(L@$^CWCN6WQN008W!VR1\!L C!&:Q_AKXTT#PEX1\6^'/%FAZGK>
ME:X]G+YFD7B6\L3V[.PR71L@[_3M53M4<EC#-DE-I]5XK15Y+5G!5R6C.+4-
M+M/=K5=?P.?\5:EX<N-<\SPM8:CIVD!4VV^IW*7$P<?>.]%48)Z#%>I_%/XH
M_#3XE:WXC\1IX6\2V/B75G:X#MJ\+VL<Q &=GD[BO'3=GWKSB]\+QS@LA ;U
M'!K$N]#N[+)V%U'I6JJIW2ZGG5<OJ4W&4D_=ZIORW[[+<]8\)_$KP2WPQL?"
M/B_P]K6IFQU:YU.WN=)U".W'[Z*&,JP>-LX\D'(QUJE\/OB1I/PX^(MQXGTK
M2KB=;..=M$@O)E=K6X92L,LIV@.8\EL #+!>U>4K,4.&!4^AJPEQ[TW)Z>1E
M&E3M*+O:5[J[MKOZ7/?M&_:F\4WMKK.D^,9_^$E\.ZQ8S6=Y9+!!;N789BF5
MTC!W)(%89X.#ZURO@C5OA^ND3VGC'1M>N+OSO,AO]"O8HV,> #$\<J%<9!.X
M'(R>#7F:7'O5A+BH<I/?7U.JG1HP35-<E[?#IMZ?T]#U7Q5\5T\3_%BR\7)I
MIL[2RFLOLUAYWF.(+8(L:M(1\SE8QEL=35[XC^,/A_XLN-9U31?#VO:;KVHW
MKWAEO-2BFMT,DA=QL6)3W('/'O7D:3^]3I/Q4.4G>_4[:=*E%P<;KE5E9O;L
M]=?F:JS>]2K)66L^?>IDF]_SK!Q/8A6-)9,&I%ER:SEFYJ99OQJ'$ZXUR^LO
MH?SJ19>*H++[T]9??\JCE.N-<OB04X/5(35(LM3RG3&L6P]*']ZK++3A**CE
M.B-8LAZ<'JL'%.#^]+E-E6)]PI<_2H-YHW\TN4OVJ)MU+NJ'?0&Q18?M42[Z
M0M4>X4;J+"]H/+4TG--W4A;WIV(=1#R:83FF[J0M^%.QBYCB<5%(JR##J&'H
M1FAG%,+9JCGE)/0HSZ1#)RA,1]N1^59TVEW$1^4"0?[/6MPM3"U;*31YM7#T
MI]+>AS+LT;8<%3Z$4TR\=:Z255D7#J&'H1FJ$^EV\GW5*'_9-:J:>YY=3"S7
MP.YD>;2>:/6K,NC2+GRY%8>C#%4IK.YBSF(D>J\UHFF>?.-2&Z'>=33-5;+;
MMNT[O3%3Q6%Q+SLV#U;BJT1@G*6B0&;WIAD%7H]( YEDS[**M165O%]V,$^K
M<U/,D;*C-[Z&0D<DYPD;-]!5F/297_UC*GZFM7<!Q2;ZGF?0W6'@OB=RK'I4
M"?>S(?\ :/%=M\*-=7PAXWL=433)M16WCFW16: SQ Q,IGCR" \>?,4D8!09
MQUKD3)5K2-<O] U&&_TN^N-.OH3F.YM)6CD0XP<,I!'!(IIM-,=2G"5.4$MT
MT>R>,/!1U2"Z\9>(-9UCQ98O96<MF8H%MM1GBEDFB#3AE?;L,#*6P^XLF&P<
MBO<_ 2&/Q)H6E6]U?WWV_P 3#19FBA&^"$Q6\FYE .V51.X8$D QGT->87/C
MSQ'=ZW)K$VOZG+JTB"-[YKN0SLO92^<XZ<52LO%.KZ8)Q9ZM?6@GD$LWDW+I
MYC@Y#-@\G/<\UKS0>Z/-5#$PC:-1+RMIM9=MM]$KWV5D?03Z!X0T3PGJ8BTV
M_M8G\#/<7<R31R27+KJZQ C]V KDH 7Y 7 VDCYO%?B+X6M?"OB&"UTU[BXL
M[O3[34(!<8:9%G@638Q4 ,5+$9 &<9P.E8$GB'47MC;MJ%TUN4:,Q&9MFQF#
MLN,]"P#$>HSUIMOXCU.RU.UU&#4;J#4+39]GNHYF$L.T87:V<C X&.E$I*2M
M85"A4H2E+GO>^_RL>\>-_AUIVI:CH%YJB:M//>1Z1H0M-(1/,M)/[.MF:28,
MK9),F%C^4G8_S#%8W_"E/#EM!IEI-JNJ7FLSP:K>S?84B,#P6,T\9$.?F9Y!
M""O91DG=TKR+_A--=CO;^\36]12[OR3=W"W<@>X)ZEVSECR>M9R:_?VTEG)#
M?7,4EE_Q[/'*RF#)+'80?EY)/'<FKYHMWY3D5'$0@HJKM_D_UMZV/>/%_@[1
M=2\&^'=:DLM8BTW2/"MO.NEQ/&;V9IM1ND#-)Y6T(N,E_+/5!CG-1ZM\$/".
MC:UI=E<WVO$ZKX@AT2WC4PAH5EMK:7S9"4^8JUS@J -P'5>_B$OCOQ VI+J!
MUW4C?K&85NC=R>:$))*!LYVY)..G-5;CQ#K^I7$<\NH:A<3QS"X266=V990%
M D#$\-A5&>ORCTJN:/5'.J.(3M&IIKMY_P"3OKUN,URWDTJ]O+5\MY,TL DV
MD!RC%21^(KWF&TN&_:4\+:@MJYTO^P+*_-T(SY/V=-(422[NFU2K GL01UKP
M_7M6U?Q-:Z1;:A-&EOI=L;6WC0'A3(TCL?5V=V+-WX]*GB\5^(+7PP_AP>(]
M7.@/G=I0O9!:G)R1Y0.W&><>M*,HQ*KT*]>/1.S7R=M?73;\3T+5O ?A/4O
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MA]GHHKDQ5*#DI6U/HN'L?B8494E/W8[+32X@_P""?WQ&_P"@OX7_ / NY_\
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M_B4!_P ACPK_ .!ES_\ (]%%=#IP['A1QV(_F_!?Y$J_\$_/B2N/^)QX6_\
M RY_^1ZE7]@#XD#_ )C'A?\ \#+G_P"1Z**7LH=CH6/Q/\WX+_(E7]@/XCC'
M_$X\+_\ @9<__(]2+^P-\1EZZOX7_P# NY_^1Z**CV4.QO',,3_/^"_R)!^P
M3\11_P Q?PQ_X%W'_P CU(O[!?Q$_P"@OX8_\"[C_P"1Z**7LH=CH68XK^?\
M%_D2#]@[XB#_ )BWAG_P+N/_ )'IX_80^(8_YBWAG_P+N/\ Y'HHJ?8P[&RS
M+%_S_@O\AX_82^(7_06\-?\ @7<?_&*>/V$_B$/^8MX:_P# NX_^,445/L8=
MCH69XO\ G_!?Y#A^PK\00?\ D+>&O_ NX_\ C%.'["_Q!'_,6\-_^!=Q_P#&
M***ET8=C6.:8S^?\%_D+_P ,,?$'_H*^&O\ P+N/_C%/7]AKX@_]!;PW_P"!
M5Q_\8HHJ?8T^QJLUQG\_X+_(7_AAKX@?]!7PW_X%7'_QBE_X8:^('_05\-_^
M!=Q_\8HHI>QI]C7^U<9_/^"_R%_X8;\?_P#05\-_^!5Q_P#&*#^PWX__ .@K
MX;_\"KC_ .,444O8T^P_[5QG\_X+_(3_ (8;\?\ _05\-_\ @5<?_&*7_AAO
MQ_\ ]!7PW_X%7'_QBBBG[&GV#^U<9_/^"_R#_AAOQ_\ ]!7PW_X%7'_QBD_X
M8:\?_P#05\-_^!5Q_P#&***/8T^P?VKC/Y_P7^0A_8:^('_05\-_^!5Q_P#&
M*:W[#'Q!/_,6\-_^!=Q_\8HHIJC3[$/-<9_/^"_R&_\ #"_Q _Z"OAO_ ,"[
MC_XQ2']A;X@'_F*^&O\ P*N/_C%%%4J,.QF\TQ?\_P""_P AI_85^(!_YBOA
MK_P+N/\ XQ2']A/X@'_F+>&O_ NX_P#C%%%'L8=C-YGB_P"?\%_D-/["7Q!_
MZ"WAK_P+N/\ XQ3#^PA\03_S%O#7_@7<?_&***KV4.QF\RQ7\_X+_(DC_8(\
M?,,OK/AP9_NW-Q_\8JPG[!?C5.NI>'7/^U=W'_QBBBL73CL>I2QM=14KZ^B_
MR)_^&&/'.W;_ &CX:QZ?:)__ (Q4$G[!OC63KJ'AL?2ZN!_[0HHJ/9070VEF
M.)DK2DG\H_Y$$G[ ?C=N1J_A]?\ M[G/_M"H'_8 \??PZWX;_&XN/_C%%%:J
M$3AGBJS5[_@O\B"3]@/XB)TUCPR?^WJX_P#C%1?\,#_$7_H+^&/_  +N?_D>
MBBMU2A;8\:>/Q*=E+\%_D(?V!OB+_P!!?PQ_X%W'_P CTG_# OQ%/_,7\,?^
M!=S_ /(]%%5[*'8P>88G^?\ !?Y#6_8#^(V/^0OX7_\  NY_^1Z8?V OB,?^
M8OX7_P# RY_^1Z**/90[$/,,3_/^"_R&C]@#XCM_S&/"X_[>[G_Y'IW_  [V
M^(K?>USPP/I<W!_]H444>SCV*IXVO+>7X(4?\$\_'W\6M^'&^EU<#_VA3Q_P
M3W\=+_S$_#3?[UY<_P#QBBBI]G$W>+K+9_@O\B1?V O'\8^34_"R_2ZN/_D>
MF/\ L"_$5NFK^&/_  +N?_D>BBG[*'8SEC\3_-^"_P B"3]@#XCL.-8\+_\
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&CNWJV?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>5
<FILENAME>mmsi-20250516.xsd
<DESCRIPTION>EX-101.SCH
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  10.10.0.1 -->
<!--Based on XBRL 2.1-->
<!--Created on: 5/20/2025 5:00:42 PM-->
<!--Modified on: 5/20/2025 5:00:42 PM-->
<xsd:schema targetNamespace="http://www.meritmedical.com/20250516" attributeFormDefault="unqualified" elementFormDefault="qualified" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:us-gaap="http://fasb.org/us-gaap/2024" xmlns:srt-types="http://fasb.org/srt-types/2024" xmlns:us-roles="http://fasb.org/us-roles/2024" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:currency="http://xbrl.sec.gov/currency/2024" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:naics="http://xbrl.sec.gov/naics/2024" xmlns:srt-roles="http://fasb.org/srt-roles/2024" xmlns:country="http://xbrl.sec.gov/country/2024" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:srt="http://fasb.org/srt/2024" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:exch="http://xbrl.sec.gov/exch/2024" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:sic="http://xbrl.sec.gov/sic/2024" xmlns:us-types="http://fasb.org/us-types/2024" xmlns:negated="http://www.xbrl.org/2009/role/negated" xmlns:stpr="http://xbrl.sec.gov/stpr/2024" xmlns:attributeFormDefault="unqualified" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:deprecated="http://www.xbrl.org/2009/role/deprecated" xmlns:net="http://www.xbrl.org/2009/role/net" xmlns:dtr="http://www.xbrl.org/2009/dtr" xmlns:cef="http://xbrl.sec.gov/cef/2024" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:mmsi="http://www.meritmedical.com/20250516" xmlns:snj="http://xbrl.sec.gov/snj/2024" xmlns:us-gaap-ebp="http://fasb.org/us-gaap-ebp/2024" xmlns:rxp="http://xbrl.sec.gov/rxp/2024q3" xmlns:cyd="http://xbrl.sec.gov/cyd/2024" xmlns:cyd-8k-sub="http://xbrl.sec.gov/cyd-8k-sub/2024" xmlns:cyd-af-sub="http://xbrl.sec.gov/cyd-af-sub/2024">
  <xsd:annotation>
    <xsd:appinfo>
      <link:roleType roleURI="http://www.meritmedical.com/role/DocumentDocumentAndEntityInformation" id="DocumentDocumentAndEntityInformation">
        <link:definition>00090 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:linkbaseRef xlink:type="simple" xlink:href="mmsi-20250516_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="mmsi-20250516_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
    </xsd:appinfo>
  </xsd:annotation>
  <xsd:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
  <xsd:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/dei/2024" schemaLocation="https://xbrl.sec.gov/dei/2024/dei-2024.xsd" />
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>6
<FILENAME>mmsi-20250516_lab.xml
<DESCRIPTION>EX-101.LAB
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  10.10.0.1 -->
<!--Based on XBRL 2.1-->
<!--Created on: 5/20/2025 5:00:42 PM-->
<!--Modified on: 5/20/2025 5:00:42 PM-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink">
  <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CoverAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document and Entity Information [Abstract]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:label="dei_DocumentType" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Type</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Period End Date</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity File Number</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Registrant Name</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Incorporation, State or Country Code</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Tax Identification Number</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, Address Line One</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, City or Town</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, State or Province</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, Postal Zip Code</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">City Area Code</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Local Phone Number</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_WrittenCommunications_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Written Communications</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SolicitingMaterial_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Soliciting Material</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementTenderOffer_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Pre-commencement Tender Offer</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Pre-commencement Issuer Tender Offer</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Title of 12(b) Security</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Trading Symbol</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Security Exchange Name</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Emerging Growth Company</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Central Index Key</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amendment Flag</label>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>7
<FILENAME>mmsi-20250516_pre.xml
<DESCRIPTION>EX-101.PRE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  10.10.0.1 -->
<!--Based on XBRL 2.1-->
<!--Created on: 5/20/2025 5:00:42 PM-->
<!--Modified on: 5/20/2025 5:00:42 PM-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink">
  <roleRef xlink:type="simple" xlink:href="mmsi-20250516.xsd#DocumentDocumentAndEntityInformation" roleURI="http://www.meritmedical.com/role/DocumentDocumentAndEntityInformation" xmlns="http://www.xbrl.org/2003/linkbase" />
  <presentationLink xlink:role="http://www.meritmedical.com/role/DocumentDocumentAndEntityInformation" xlink:type="extended" xlink:title="00090 - Document - Document and Entity Information" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract" xlink:label="CoverAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:label="dei_DocumentType_638833572427920042" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_DocumentType_638833572427920042" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate_638833572427920042" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_DocumentPeriodEndDate_638833572427920042" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber_638833572427920042" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityFileNumber_638833572427920042" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName_638833572427920042" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityRegistrantName_638833572427920042" order="4" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode_638833572427930072" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode_638833572427930072" order="5" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber_638833572427930072" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber_638833572427930072" order="6" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1_638833572427930072" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityAddressAddressLine1_638833572427930072" order="7" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown_638833572427930072" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityAddressCityOrTown_638833572427930072" order="8" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince_638833572427930072" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityAddressStateOrProvince_638833572427930072" order="9" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode_638833572427930072" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode_638833572427930072" order="10" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode_638833572427930072" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_CityAreaCode_638833572427930072" order="11" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber_638833572427930072" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_LocalPhoneNumber_638833572427930072" order="12" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications_638833572427930072" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_WrittenCommunications_638833572427930072" order="13" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial_638833572427940054" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_SolicitingMaterial_638833572427940054" order="14" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer_638833572427940054" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_PreCommencementTenderOffer_638833572427940054" order="15" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer_638833572427940054" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_PreCommencementIssuerTenderOffer_638833572427940054" order="16" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle_638833572427940054" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_Security12bTitle_638833572427940054" order="17" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol_638833572427940054" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_TradingSymbol_638833572427940054" order="18" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName_638833572427940054" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_SecurityExchangeName_638833572427940054" order="19" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany_638833572427940054" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany_638833572427940054" order="20" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey_638833572427940054" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityCentralIndexKey_638833572427940054" order="21" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag_638833572427950054" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_AmendmentFlag_638833572427950054" order="22" use="optional" />
  </presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>9
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Document and Entity Information<br></strong></div></th>
<th class="th"><div>May 16, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Document and Entity Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">May 16,  2025<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">0-18592<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Merit Medical Systems,&#160;Inc.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">UT<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">87-0447695<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">1600 West Merit Parkway<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">South Jordan<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">UT<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">84095<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">801<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">253-1600<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, no par value<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">MMSI<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000856982<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14a<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.25.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>22</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="mmsi-20250516x8k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00090 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.meritmedical.com/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File>mmsi-20250516.xsd</File>
    <File>mmsi-20250516_lab.xml</File>
    <File>mmsi-20250516_pre.xml</File>
    <File doctype="8-K" isOnlyDei="true" original="mmsi-20250516x8k.htm">mmsi-20250516x8k.htm</File>
  </InputFiles>
  <SupplementalFiles>
    <File>mmsi-20250516x8k001.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="22">http://xbrl.sec.gov/dei/2024</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>15
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "mmsi-20250516x8k.htm": {
   "nsprefix": "mmsi",
   "nsuri": "http://www.meritmedical.com/20250516",
   "dts": {
    "schema": {
     "local": [
      "mmsi-20250516.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.sec.gov/dei/2024/dei-2024.xsd"
     ]
    },
    "labelLink": {
     "local": [
      "mmsi-20250516_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "mmsi-20250516_pre.xml"
     ]
    },
    "inline": {
     "local": [
      "mmsi-20250516x8k.htm"
     ]
    }
   },
   "keyStandard": 22,
   "keyCustom": 0,
   "axisStandard": 0,
   "axisCustom": 0,
   "memberStandard": 0,
   "memberCustom": 0,
   "hidden": {
    "total": 2,
    "http://xbrl.sec.gov/dei/2024": 2
   },
   "contextCount": 1,
   "entityCount": 1,
   "segmentCount": 0,
   "elementCount": 23,
   "unitCount": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2024": 22
   },
   "report": {
    "R1": {
     "role": "http://www.meritmedical.com/role/DocumentDocumentAndEntityInformation",
     "longName": "00090 - Document - Document and Entity Information",
     "shortName": "Document and Entity Information",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "Duration_5_16_2025_To_5_16_2025_vgCLfz_rmkqZlxHvigqlTQ",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mmsi-20250516x8k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_5_16_2025_To_5_16_2025_vgCLfz_rmkqZlxHvigqlTQ",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mmsi-20250516x8k.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://www.meritmedical.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CityAreaCode",
     "presentation": [
      "http://www.meritmedical.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Document and Entity Information [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://www.meritmedical.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentType",
     "presentation": [
      "http://www.meritmedical.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://www.meritmedical.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://www.meritmedical.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://www.meritmedical.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://www.meritmedical.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://www.meritmedical.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://www.meritmedical.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://www.meritmedical.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://www.meritmedical.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://www.meritmedical.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://www.meritmedical.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://www.meritmedical.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://www.meritmedical.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://www.meritmedical.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "Security12bTitle",
     "presentation": [
      "http://www.meritmedical.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://www.meritmedical.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://www.meritmedical.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "TradingSymbol",
     "presentation": [
      "http://www.meritmedical.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://www.meritmedical.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14a",
   "Subsection": "12"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>16
<FILENAME>0000856982-25-000035-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0000856982-25-000035-xbrl.zip
M4$L#!!0    ( !6"M%HGUWVXN ,  'T-   1    ;6US:2TR,#(U,#4Q-BYX
M<V2U5MMNXS80?2_0?V#]3DFVXZ QDBR:;@LLD+1%N@7R5M#4R.:N1&E):FW_
M?8>4*)NRI&2+%@@2A>?,X7 X%]Z^.Q0Y^0I*BU+>S>91,B,@>9D*N;V;U9HR
MS868O;O__KO;'RA]>7A^)&G)ZP*D(5P!,Y"2O3 [\K&L*B;)$R@E\IP\*)%N
M@9!Y$N$/_B*4MB(/3*-1*8E36T3S#OFY%2SEFJSB18(_BQ59K9-D?;4@?SQU
MQ"=T,!.O,@\Z76N^@X(1P]06S&^L %TQ#G>SG3'5.H[W^WU4@!*F@%1PED>\
M+)Q8LII?SP@S1HE-;>#74A7O(6-U;C N\DO-<N<!ABL'&XV < 9C?*5>HR?!
MEOME5*HM;I3,XY>GQS^=DYZ<@NC(AXW*(PT\VI9?8P2L;U>>B/>S9:SJR!G3
M&Z?; @%9*T/-L0)]2>^@OKHJ\R&^1P*Z@BPXHO.\/>1UC&@7"P12$YZPY:WB
M!O147BN%Z7@<#H=' S<.^:@7R_CE4<C/GBF9X'I8V4$7T1N)1@<%!KRLI5%C
MGC=@&&ZC1CV_B1$]<V70B4 MQX-.!,+"&ZQ#3X<#WPV[:I%>@/O2;3+/;VYN
M8H=VG@H^+(I /]5&4M,C 5W"UO:)B7#9^XA;6N>-J=2(.X@$&[RA['U=B]?K
MF@JI#9,<SBM 3-Q.GP^R+A9#!8.-#PX&I!:;'*BE@6(&6[FF"]O*VWYB5"^\
MP98(QQ:V>@N:+.ER?NI$E0+^EEB?F*=+,J]?D#GS<8*=GK*?G[69L*8@"_/4
M=A(QV&:NFS8C/+4H>M<X,1':7)*?1E))?AIJT10VXVW:@F$K/53#Z@@XXI=E
M%XYC.A*.8QKVHV-*?_Q,=;T9Y;?XA1G+ILT:O#'#L4N(&[Q,RM*X9'1K?K6J
MA,S*=@D7;;]8VVSXB"E([,=?SQ^F+\/ESOOV%>+__B337Z01YO@!Y57A-IX1
M@=%Y$[-SR+N40B:D<.XGF(()H<0+G'\RF9)&C9S)W<9]C;Y\C6^@W^6]^\;*
MT:CE+.V :JU;RI0E1H37^;\P/'DV;M>N^KOI79F?(,^0$=?TU[:'W,VT**K<
M=BZWMG.O EM?U)?0WWC<")/+4ZS^1"]TE]V/4+NQEV"*7ZA<#"44*2M01N P
M.8V_^#\[5LXVWWHL-('\_SG/;=ROMG8EK$I7DWBT4ADB!Q_'8Y.I>5<_EMR)
M39C8_[H)2.T2G2]PQD2XM?=WVHWA%^(;'? &=N?5-^YY^>X>VE2/T>V'S8^K
MT[;-)30J]_\ 4$L#!!0    ( !6"M%K%W?#]: 4  .\[   5    ;6US:2TR
M,#(U,#4Q-E]L86(N>&ULU9OO;^(V&,??3]K_\(R]V:0+ 7I]4=3VU'*]"8U>
MT<&TTZ;I%!(#UA(;.:; ?S\[B5.2VH$+762DB@:>K[]^'O.I?T!Z_6$;A?",
M6(PIN6EUVYT6(.+3 )/%36L=.U[L8]SZ</OC#]<_.<[7^R\C"*B_CA#AX#/D
M<13 !O,E3.EJY1%X1(SA,(1[AH,% NAVVN)'/(#C9";W7BP:40*)6Z_=S2.#
MS)"2/ERZO8[XZ5W"9;_3Z;_OP?@Q%SZ*!.?XH#+$Y-^^?)B)+D%42N+^-L8W
MK27GJ[[K;C:;]N:B3=E"M.]TW:^/HXF_1)'G8!)SC_BH!4+?CY,71]3W>#),
M>\VW,Q8J@PLW[\NHD,\<)7/D2TZWYUQTV]LX:&4IRO 1G2BYC 8\;[ OOG33
M8"Y]99V5W[VZNG*3:$L,'$ V=-X,A2-Q!4FHSW<K=--"6XY(@&2ZR:N,AJ@B
M71EV7YRE-_4+AJ$<6,J4WY*A>>H7JW)BY+<7]-D-$);O]'MYX<@+.6P_BR??
M!E1 ?#>+.?-\KIR2_&]:NK@<CJ/&V,VSEF9WK)BZQWS5F;@\,!*9PO6I(&O%
MG<11-9\S&NE33;NCFN"W<!;6KZ50"$,Q7;,$^./?U/W\36.=YR@4<DY!Q/EC
M\AU)WWY4TXU' G@@'/,=#,F<LBCY:X2_54__7*<9_9^8J62FPE%3>2EL,62Z
M0A1C^S%+$=.F>#)ATJU!B,:(81H\D."C6/4JBBSKS@ K;6EEO@HBRT'3YWHR
M<:FMF-8"D,8-P)?.H)]PB#ZOHQEBFIHU$HN1,Q6D:"O'+07-F&9=QK*E4CI"
M:MD875_0 LLUF?#/7J2;V0PRZRG3%U8DK:BQFC9#JB<2]^(*TK8QZH;BW,I6
ME"7;P@D7T^F K@EGNP$-S! >:F4]DT>5742TLHG5Q!Z7^8D %SIY!TDW0!ED
M78'LJS&JI]YV&(BM I[C]..' \NV66\]R0=*+3)L$%M-[Z&<3^16V$/1O^F%
M_RX(Q*C%V:\1)JAK' R]UGI(*THL JH16@UG5;XG@IEYOE,7(-WAB30WBV8=
M#\3E$YO2#3DT# 7EN4#YNCPMDB^R<P!2D^U;X2BMY<(NS9M&,=E5/+$QH\^8
M^.;]J5%^+E :"M626=*> YZFE-^*T7SWJ7IH&M0QC;D7_H57E<<H@_A<(-46
MJ46TH#P'0/4)OQ6>J3L(^Z:.17+2OF/(,^!8"EL,H*Z0_&N^O9BED&E3K(M5
MLA)+MZ8HDE_FA^,E)>:/P342BVDR%:2(*L<MI<J89EVR$D-(')L[#?_),.>(
M#&@4K4EV%H\UU9IT%G-669J"32NRE+CJ7.MBE[E"T;8!]"8TQ#[FF"P>Q<:1
M84]7LU9D,73FHA1QKQ66XE:1:%W67BQ!>38 VI@A"3<2;UQR)X:\)XP]S>?:
MM;12;#%XAXM4 )J5EH)X1,)U@136CK_G#:DY).[-HSF,XS5BWP6HKLGY8&HL
MV #K*_UY(&M.^\W 3;MHFM\)\M=B_[#K]F93S$/=,5<CL9A/4T'YZEV*6\J?
M,<VZO"4N0.?0[?TR^Q64?P.(39DG[_&?[*(9U95:CEL,E[84158A:"E6^AQK
M,Y6Z06K7X&SUL/67(F5DN.?+(+,8K*K"RC/7OL92S"I3K7WVR$Q!N39[S]=#
MA-A"T/X;HQN^%)N#E4=VQD_$36J+&3RBS.+7%%JII40>D_&)7U0H<TC=(;-O
M#-"!V$4R+QR*_>/V=V1&\[7.>B@-I15Q+(FL!M&4ZXD(9K:0^((P;@"^.W%Z
M">0)YE/H+30%E^,6PZ8M14%6"%H*ES['NE#E;B#M]E&Z=E]Z'HDK^1^PV4M9
MZ]O_ %!+ P04    "  5@K1:KZ[GX7D$  #\)0  %0   &UM<VDM,C R-3 U
M,39?<')E+GAM;-5:78_B-A1]K]3_X$V?0SZ F0$-NV+8V0KML(,&5EWU9642
M U8=.[+- /^^=H@I@00R51LF$H(0GUR?>X[C^":Y_[2)"'A%7&!&>Y;7<"V
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M>P"N?P);RD^Z9O'W?Z4<SU2_!4$8.@;&;%WO($)4XOXY.1*-ST:?981?F_9
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MJU@)IL\P!3(793QN]AYRH'C,/)YT]"'Y'*EXP"IT14DO#(!@HVVL,25<X['
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M6Z/*09KI+9S.IL-1E*#KD'EF"P\3WSQM\B=XDHV"W,MRM9DG;3(.373K<<%
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MLD0.\\R.D7M_Y5(?(9 2D?44P3$)AY9%@PE&F8#;T"L]TU(D]G@Z*=M4IQ2
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MJ#5ZY<"6->U'TZE,E<"ZAZB?'.S;8],):-%A,47\K74+7G% 2C4K3$D5.BF
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MR4J[>(2@\)*Q07HBL!IQIDK(U(=6E-S2=$U^9U![RG%-+%%LTJJPT95G5/A
M.L>J-*C: *'+>Y5SX'AD2XJ$C7]4<8!4TPKFG1*?HN#6CLB9RF"!!M3_;")4
M(QK0% +8(:G\;XO!IJ_.A'*]BLM:T#TJ/D=\H?+/UH6DVI)T0CSCNL4F'T:C
M5U27.H&C0UDN!8QFL^2L3.*B)2TQ-4LHQQ7C74]JN\36/YL2Z=)[*^T-58GF
M:,X\5,DBUW01WRCT19YWX;SJ,JHTUJXORSAD9X27_#PS7>OVK/\\N"EKUIC.
M,EIA?@E%R,4J;B544&>)7[J\Y<QJG**XQ]9U.UT8-49]J/;V(7I%I<7O4:"K
MK#]^W"<9_02=1%6%5$VWK@O[0C_ZP"D)Y[$3FV^UE1DA^P<A+#W<6E(YN$1B
MU* =UB^Y4Z=V5R1%ND#?(<Z@X%FG %NKR3 5?^7&&A[9BO"(DIY4\G#. UUF
M6 ^$J-C'@&QM'?VI/[+6@3]$80+EG) Y=R)"V@OS*2(E287$H-M.89<4+_Z0
M> XH_9KD<8&RU;:HZ(.V8TQ4%7N98%?)+ H"X.DB$*-,>^*9@18LZGT<1$-*
MW4:!KEMI%<&6EMX%D$D2HA;H)J=#JNPO5LBA9!F7H:T_>LN.2>9*DYO7_!.#
MS<@H\JB>?%&N=)_0\:%9/<T%"9\5%HZ25OLZ68.TRT)IO<IF!0M)VEO7!=^U
M);8>"=EH)2.#LXA(M%-I;DQ) MN9JHW5I6\5H82? @Y7AE=5="NM:BX"(?6V
M)H46H@0"1QMI\"H";VXXC1P&;Z+]!2LOHJ@/HO$2W!1;1,QHE5\D5*6IBY#&
MZG(WJ0PJQQ4695,BS;0O>-E)AT:-AB.]V^)BC7 5DI;UP<YD4ULP5B5QN82D
MG"B@Y$VTE*<Z[SK7$G8>!>?:L"QV@SB:"3QYSCW]J,\S3F3*="IW4-U9DGH)
M\#&<N^SO&!K5XK.BN,(==:4Y&=)2&=0G2]=LF$F-J)1[9'#;3$&1:Z"L,JI+
M,TJVY/%*Z5PFT@)ZE^ >I(W"7<H*T/L9E=UN-YA<A(AZY\I(9',5B<"4#?%L
M08[Z>S)/@=P<9J$?Q99*%S5YD=$@P@2V;JD3C!M&346A"HIJM:)YN2B%RQ10
MF#DE9X*L;=!?7 H'Q6"FD:_VP]B]2V4DG_JM;S52W)/1:L.64*2K(J6U> ;N
MCJ@2VO[$N)1"K&R)TFA1+G>5V<EG(NU/^[<@]U6CAOL8GZZ */6>K)/>[@O3
M%LI8X2W,$S+(2L/KO9'X_2@A#<2^) 04GBV#L#T&?&;LN4*Z!M7NZS+/J<DX
M4AAXJ-"01'5OG B;<8'X:I6?S82PCKTIU-2#^TV0R:2S#B.8*93_%*1]E"EC
ML+2N+@,)B?.50JK$[ OTK6UL(VO#%T-T;<>FU,^(]*NP?5>[<%#+&,QDG"4:
MT1;S3,[CMEV]W4N%K36GNSF106$PD;43! 56J&NT$4OK'"_@<DI/5R"RW$.6
ME8Q2WT970\J!^T3&O^GUKB)@:BMWOX:2UHV*SURF_!-@G)8^OPJ91:G2/VJ3
MFS1E8=1\L^GJ"6ZZNLM8HA4"@L4RY6?8G=POA:YU0+0&FN)!0J9!9<^L\AP,
MLT]DG"XS7I0Q+D6BH\ CF+\JKF6\E>*NVN.L+?Q!-7LZJN9=%=Z5^."$;A**
MKB4+\1CM"3O676E)TF?.!4W**$0J'HTSJ^K=;@?,%JO2O; LMX_TT*L6Z7(E
M2G!@-]+69#_/4NF72F90T$DW3=Z,UA%$+4]O. W/91)9G4OP4\&D,S$G>J91
M&(H :I8/]4ZOA$YOL':IXS'H![PHS12:2F/]6 PMO!XR_VA'-X">S037.[S/
MM0Y0KI.("K?)W-!;>SG(GZC'J70V3U/'1KS(+'88=1E[6EW5J@>N2H^Z\,%:
ML'X%[07*V"$<>1C.K+=7E&<=8P#LO=[<;.N%%MS*O3"D,."QVM%,3(!IH95N
M^Y]%&,CN503:VZV*S.Q27*<MA5;7KV!#8<M,YKJS^9>N2P=G+4[H7\6$3/6Z
MF=,13[ >Q;;+VH0PN"7A$%N?4=M.B8?O/^Z\2H#="VBWR5#;=]EE>9OZL0G:
MCM.E&ZEB86WF4JT$'A^*"0]&*JIM<FI8,U7>7VYEI1W>9-$D\#],F# M<@.T
M!<C-7NQ]7RJ%Q.ZB1(H;@2H2$_>:%3E56TB=CJD+JD6R6<LKBHB7)]$H)8QU
M(/U8Q*GI>^_Z[_)ALZ?I&ZD/]2CU.I,IS<=$'H9S%[V!UW;_ETJ/J4-.H) "
MZPQ1)B?676G$#"+5&IU)1,2@\,D/3_:>MPSDUY.M6]PA<'J\]]O!T=[Q/T_>
MO,Z?"!!]#=7&5LB6\$M&;.E< QDZA9]""0X5%"OOV*V!"Y*0Z?T[$#R]J>B2
MO8NJ%'=M9T#@18@(WY+K@ X=0I*1P^F)D#8IW\M9$C?W8<XC,,\5+LSK8>3/
M\9])-@W>_A]02P$"% ,4    "  5@K1:)]=]N+@#  !]#0  $0
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;,2YH=&U02P4&      8 !@"2 0  _8(

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>mmsi-20250516x8k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2024"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="mmsi-20250516.xsd" xlink:type="simple"/>
    <context id="Duration_5_16_2025_To_5_16_2025_vgCLfz_rmkqZlxHvigqlTQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000856982</identifier>
        </entity>
        <period>
            <startDate>2025-05-16</startDate>
            <endDate>2025-05-16</endDate>
        </period>
    </context>
    <dei:EntityCentralIndexKey
      contextRef="Duration_5_16_2025_To_5_16_2025_vgCLfz_rmkqZlxHvigqlTQ"
      id="Tc_cVzWQdKh7kOiNbVtHlxGPg_2_1">0000856982</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag
      contextRef="Duration_5_16_2025_To_5_16_2025_vgCLfz_rmkqZlxHvigqlTQ"
      id="Tc_KhXYW36uuEW1aAv2WAzdyQ_3_1">false</dei:AmendmentFlag>
    <dei:DocumentType
      contextRef="Duration_5_16_2025_To_5_16_2025_vgCLfz_rmkqZlxHvigqlTQ"
      id="Narr_xDzag7Udt0ujWC-nlgPdKw">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate
      contextRef="Duration_5_16_2025_To_5_16_2025_vgCLfz_rmkqZlxHvigqlTQ"
      id="Narr_tUvifcr_jEK_s2eIyZZI2g">2025-05-16</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName
      contextRef="Duration_5_16_2025_To_5_16_2025_vgCLfz_rmkqZlxHvigqlTQ"
      id="Narr_58dpc45oIUyGiSTYjamg7Q">Merit Medical Systems,&#160;Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="Duration_5_16_2025_To_5_16_2025_vgCLfz_rmkqZlxHvigqlTQ"
      id="Tc_2WEFPxN60EuHJrjG6jbXHg_1_0">UT</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber
      contextRef="Duration_5_16_2025_To_5_16_2025_vgCLfz_rmkqZlxHvigqlTQ"
      id="Tc_gbmZwn46Hkq5xuXdNfMZgA_1_2">0-18592</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber
      contextRef="Duration_5_16_2025_To_5_16_2025_vgCLfz_rmkqZlxHvigqlTQ"
      id="Tc_anGvr-2npUKO5VRv7kSyrQ_1_4">87-0447695</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="Duration_5_16_2025_To_5_16_2025_vgCLfz_rmkqZlxHvigqlTQ"
      id="Tc_X0WT8NOqSEWklHwtT9eHxw_1_0">1600 West Merit Parkway</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="Duration_5_16_2025_To_5_16_2025_vgCLfz_rmkqZlxHvigqlTQ"
      id="Narr_C0UeGfh5e0W-rHKMfQrl8A">South Jordan</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="Duration_5_16_2025_To_5_16_2025_vgCLfz_rmkqZlxHvigqlTQ"
      id="Narr_U0ztLyHDfEG3FuIcYp60OQ">UT</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="Duration_5_16_2025_To_5_16_2025_vgCLfz_rmkqZlxHvigqlTQ"
      id="Tc_EIDu67yFSkeAvU1jJXbe1w_2_2">84095</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="Duration_5_16_2025_To_5_16_2025_vgCLfz_rmkqZlxHvigqlTQ"
      id="Narr_hEwSPIleuEm3CnQgHsSZOw">801</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="Duration_5_16_2025_To_5_16_2025_vgCLfz_rmkqZlxHvigqlTQ"
      id="Narr_7CGCoarYP0qoPorSwfoYWA">253-1600</dei:LocalPhoneNumber>
    <dei:WrittenCommunications
      contextRef="Duration_5_16_2025_To_5_16_2025_vgCLfz_rmkqZlxHvigqlTQ"
      id="Narr_-DGH9K7K5kavZd8xC-_AQA">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial
      contextRef="Duration_5_16_2025_To_5_16_2025_vgCLfz_rmkqZlxHvigqlTQ"
      id="Narr_t0QZxMttZUOwlnc2G5G7tA">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer
      contextRef="Duration_5_16_2025_To_5_16_2025_vgCLfz_rmkqZlxHvigqlTQ"
      id="Narr_zPhKa0aXm0Cj_QJWq6P27g">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer
      contextRef="Duration_5_16_2025_To_5_16_2025_vgCLfz_rmkqZlxHvigqlTQ"
      id="Narr_In9Ejc358kKFgiwdwCEg2A">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle
      contextRef="Duration_5_16_2025_To_5_16_2025_vgCLfz_rmkqZlxHvigqlTQ"
      id="Tc_CmtpGVuv90CyTEtOljToug_2_0">Common Stock, no par value</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="Duration_5_16_2025_To_5_16_2025_vgCLfz_rmkqZlxHvigqlTQ"
      id="Tc_R9AmYcDbE0i0QRm1gLDE0Q_2_2">MMSI</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="Duration_5_16_2025_To_5_16_2025_vgCLfz_rmkqZlxHvigqlTQ"
      id="Narr_8HRJ3VKim0yYh7xZsLUlaw">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany
      contextRef="Duration_5_16_2025_To_5_16_2025_vgCLfz_rmkqZlxHvigqlTQ"
      id="Narr_1iydx7MW70O9afTUAVnWqw">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
